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ABSTRACT
MELANIE A. MOSER
A Descriptive Review of Balamuthia and Non-Keratitis Acanthamoeba Cases in the
United States, 1955-2009
(Under the direction of Richard Rothenberg, Professor)
Free-living amebae are ubiquitous in the environment and occasionally invade and
parasitize host tissues causing illness in humans. Despite possibly frequent exposure to
these organisms, infection is rare and why some people, healthy or not, end up with
illness and others do not is still unclear. Human infections are rare; when illness does
occur, it is often fatal. Only two papers have examined data from the literature and cases
reported to the Centers for Disease Control and Prevention, and both were published over
twenty years ago. The purpose of this study is to better document the epidemiology of
Balamuthia and non-keratitis Acanthamoeba, give insight into trends of these infections
over time, and contribute to the scientific and medical community by producing the only
comprehensive review of all Balamuthia and non-keratitis Acanthamoeba cases in the
United States from 1955 through 2009. This study also examines cases that have
survived in an attempt to determine if there is evidence for the effectiveness of a
particular treatment regimen. Only a small number of patients have survived these
infections, so any evidence for a successful course of treatment could be crucial for future
cases.

INDEX WORDS: free-living amebae, Balamuthia mandrillaris, Acanthamoeba spp.,
non-keratitis Acanthamoeba
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CHAPTER I: INTRODUCTION
Background
Free-living amebae are ubiquitous in the environment and occasionally invade
and parasitize host tissues causing illness in humans.1,2 Although human infections are
rare, when illness does occur, it is often fatal. There are four genera of free-living
amebae known to infect humans.2 Naegleria fowleri, which can cause primary amebic
meningoencephalitis (PAM), is described in the media as the “brain-eating ameba”3,4 and
news reports of infections with this organism have likely raised awareness of free-living
amebae. Other free-living amebae, such as Balamuthia mandrillaris and Acanthamoeba
spp. can cause granulomatous amebic encephalitis (GAE), an infection of the central
nervous system. Although there is only one species of Balamuthia known to infect
humans, B. mandrillaris, there are multiple species of Acanthamoeba, at least eight, that
can cause human infection. Acanthamoebiasis and balamuthiasis can manifest as
disseminated infections throughout the body or localized in an area of the body, often
affecting the brain, skin, and/or sinuses, as well as other organs such as the lungs, liver,
kidneys or lymph nodes, either independently or in combination. Acanthamoeba spp. can
also cause keratitis, which may threaten an infected person’s vision by causing ulceration
of the cornea, diminished sight, or even blindness. Sappinia diploidea also has been
identified as the cause of one reported case of encephalitis.1
Naegleria fowleri has been isolated from warm freshwater, geothermal waters,
soil, sewage, and unchlorinated or minimally chlorinated swimming pools.5,6 Likewise
Acanthamoeba spp. have been found in soil, sewage, swimming pools, and freshwater but
1

2
have also been identified in hot tubs, sea or brackish water, heating/ventilating/air
conditioning (HVAC) units, dialysis machines, contact lens solutions, and intra-uterine
devices (IUDs).6 Balamuthia mandrillaris is found in soil.7,8 Balamuthia might also be
present in freshwater; there have been reports of Balamuthia GAE in dogs that swam in
ponds but there have been no reported human cases where the only potential exposure
was swimming.9,10 Because these amebae naturally inhabit so many locations, it is likely
that humans are frequently exposed to them. Immunologic studies of N. fowleri,
Acanthamoeba spp., and B. mandrillaris have shown that some humans have antibodies
to them.1 Two serologic studies carried out in the United States showed that persons who
had extensive contact with freshwater lakes had antibody response to N .fowleri.11
Antibodies to B. mandrillaris and Acanthamoeba spp. have been demonstrated in healthy
as well as hospitalized persons.1 Despite possibly frequent exposure, infection is rare and
why some people, healthy or not, end up with illness and others do not is still unclear.
Culbertson was the first to suggest that free-living amebae could possibly cause
infection in humans and showed pathogenicity using animal models.2,12 Butt described
the first U.S. cases of free-living ameba infection, PAM caused by N. fowleri, in 1966.13
Less than ten years later in 1972, Jager and Stamm reported the first human case of
Acanthamoeba disease, which occurred in the U.S, although it was another eight years
before it was definitively recognized that Acanthamoeba was the causal agent not
Hartmannella as was supposed in the original case report.14,15 Eventually several reports
preceding the 1966 first report of free living ameba infection were retrospectively
identified as cases of Acanthamoeba spp. as understanding of the organisms increased.2
Recognition that Balamuthia (referred to as leptomyxid ameba at the time) was also a
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cause of human infections came in 1990 with a report of cases of GAE due to
leptomyxid; the first U.S. was later retrospectively identified as occurring in 1978.16
N. fowleri primarily affects immunocompetent children and young adults and
without treatment has a rapid clinical course resulting in death within 1 to 2 weeks after
exposure.1 In 1980, Martinez was the first to note that Acanthamoeba is an opportunistic
infection affecting persons with chronic illness.17 This characterization seems to remain
true as most reviews consider it to be an infection that typically affects
immunocompromised persons.1,2,17 It is thought that there is a subacute phase of
infection and the timeframe has not been well characterized, but once the acute phase
commences, the infection can be fatal within weeks. B. mandrillaris has been reported to
affect both immuncompromised and healthy individuals.1 Of note, recent reports of
Balamuthia infection via organ transplantation raise concerns for the organ procurement
community.18,19 The clinical course of balamuthiasis is thought to be the same as that of
acanthamoebiasis. Like Acanthamoeba, Balamuthia can also infect tissues outside the
central nervous system.1 Unlike with Acanthamoeba and Naegleria, it has been reported
that being of Hispanic ethnicity may be a risk factor for B. mandrillaris infection.1,20
There are subtle differences in the routes of human infection among the freeliving amebae. N. fowleri enter the nasal cavity, attach to the nasal mucosa, cross the
nasal-brain (cribriform) barrier, and invade the brain. This invasion results in
hemorrhagic necrosis as the amebae lyse or ingest red blood cells and/or digest or destroy
brain tissue through secretions in their food cups.1,11 Acanthamoeba spp. is thought to
invade the body via the nasopharyngeal route, breaks in the skin, or by inhalation of
cysts. The organism also produces food cups and secretes enzymes that may aid its
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spread throughout the body. Balamuthia is thought to have some similarity to
Acanthamoeba in its route of infection and its possession of particular enzymes that aid in
its invasion process, but little is known about its pathogenesis.1
Meningoencephalitis is the swelling of the brain and its membranes. Butt first
introduced the concept of primary amebic infection to differentiate between Entamoeba
histolytica’s secondary infection of the brain (via the bloodstream) and Naegleria’s direct
infection.11 Later, Martinez differentiated between the manifestations of free-living
amebae infections caused by Acanthamoeba and Naegleria, particularly the changes
occurring in the tissues of the brain, giving further distinguishing differences between
PAM and GAE. PAM was characterized as “severe acute necrotizing and hemorrhagic
meningoencephalitis involving mainly the base of frontal lobes and posterior fossa” (p.
570) with lesions located on the surface of the brainstem, cerebellum, and cerebral
hemispheres.17 GAE’s characteristics included: leptomeninges with moderate amount of
purulent exudate over most affected cortical areas, moderate to severe edema in the
cerebral hemisphere, and “foci of encephalomalacic worsening associated with small
areas of hemorrhagic necrosis in occipital, parietal, temporal, or (less often) frontal
lobes” (p. 569). GAE lesions vary in their location and composition.17
Purpose of the Study
There have been many case reports of free-living ameba infections in the United
States, publications on diagnostic techniques and immunology, and reviews of the
organisms; but there is still much to learn about the epidemiology and clinical course of
these infections. A few case reports and reviews have attempted to summarize a limited
number of published cases of acanthamoebiasis and balamuthiasis,21,22 or have examined
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specific aspects of these infections, such as case reports of Acanthamoeba GAE or
Acanthamoeba rhinosinusitis among AIDS patients.23,24 Only two papers have examined
data from the literature and cases reported to CDC, and both were published over twenty
years ago.6,16 A recently published article concerning the epidemiology of primary
amebic meningoencephalitis caused by Naegleria fowleri in the United States gives a
comprehensive review of cases using multiple sources of information such as the Centers
for Disease Control and Prevention’s (CDC) Free-Living Ameba (FLA) Laboratory case
registry and Waterborne Disease and Outbreak Surveillance System, as well as the
National Vital Statistics System, published case reports, and media reports.25 The
descriptive analysis presented within this thesis is modeled on the methodology of the
PAM epidemiology paper and will examine Balamuthia and non-keratitis Acanthamoeba
cases in the United States from 1955 to 2009 by accessing the FLA Laboratory case
registry and published case and media reports.
The purpose of this study is to better document the epidemiology of Balamuthia
and non-keratitis Acanthamoeba, give insight into trends of these infections over time,
and contribute to the scientific and medical community by producing the only
comprehensive review of all known U.S. cases of Balamuthia and non-keratitis
Acanthamoeba through 2009. Along with bringing about a better understanding of the
characteristics of these cases, this study will also examine cases that have survived and
attempt to determine if there is any evidence for a given treatment regimen as being
particularly effective. Only a small number of patients have survived these infections,
and any evidence for a successful course of treatment could be crucial for future cases.
Research questions
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1. Are there any demographic characteristics that indicate commonality between
cases and suggest that persons of a particular ethnicity or race are more predisposed to infection? In particular, does Balamuthia disproportionately affect
persons of Hispanic ethnicity as suggested in the literature?
2. Are there any presenting symptoms that are particular to acanthamoebiasis and
balamuthiasis that would assist clinicians in early identification of free-living
ameba infection?
3. Are there any commonalities in the treatment regimen of those who survived?
4. What is the time from onset of symptoms to death?

CHAPTER II: REVIEW OF THE LITERATURE
There have been more than 60 case reviews or reports citing cases of non-keratitis
Acanthamoeba disease and over 40 cases of Balamuthia disease in the United States
published between 1960 and 2009. The first case report of Acanthamoeba disease was
published in 1960, five years after the actual case occurred, and was reported as a
granuloma of the brain, likely due Endolimax williamsi.26 This same case was cited in
several subsequent publications as Acanthamoeba granulomatous amebic encephalitis
(GAE) upon retrospective review.6,17,21,27 The first case report of Balamuthia disease was
published in 1974; although Balamuthia was not recognized as the causal agent at the
time, it was reported as a case of free-living amebic meningoencephalitis that was not due
to Naegleria or Acanthamoeba.28 The case was cited as Balamuthia GAE in subsequent
publications.6,17,27 Appendix A has detailed tables of all published Acanthamoeba and
Balamuthia case reports.
Disseminated infections
A review of the literature reveals Acanthamoeba disease manifests itself in
various ways (disseminated, GAE, cutaneous, rhinosinusitis, osteomyelitis) as does
Balamuthia (disseminated and GAE). But unlike Acanthamoeba, disseminated
balamuthiasis always involves the brain. Disseminated Acanthamoeba disease was the
most frequently reported manifestation of acanthamoebiasis in the United States, with 29
cases published in the literature. [See Appendix A, Table 1 for all disseminated
acanthamoebiasis case references.] The majority (n=19) of reported disseminated
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infections were in patients who had human immunodeficiency virus (HIV) or who had
acquired immune deficiency syndrome (AIDS). [See cases 5-11, 13-19, 21, 22, 24, 25,
and 28.] While HIV/AIDS was the predominant cause for immunosuppression among
case patients with disseminated acanthamoebiasis reported in the literature, it was
followed by those with a previous medical history of organ transplantation and
immunosuppressive drug therapy (n=4; cases 4, 23, 27, and 29) and bone marrow
transplants due to cancer (n=3; cases 12, 20, 26). One case was reported as having lupus
and two case reports cited no known predisposing health factors (cases 3, 1, and 2
respectively).
The most common form of disseminated Acanthamoeba disease was a
combination of skin and sinus infection (n=10; cases 5, 8, 11, 13-15, 21, 22, 24, 28),
followed by cases with a combination of GAE and cutaneous infection (n=3; cases 6, 9,
20). There were two reports of patients with GAE, cutaneous, and lung disease (cases 3,
29), two reports of patients with GAE and lung disease (cases 10, 26), and two cases with
cutaneous infection and osteomyelitis (cases 17, 27). The other disseminated
manifestations varied greatly among the patients. Those cases that included GAE and
other manifestations were: GAE, cutaneous, and sinus (n=1; case 19); GAE and keratitis
(n=1; case 1); GAE, lungs, and adrenals (n=1; case 12); GAE, cutaneous, and pulmonary
hyaline membrane (n=1; case 4); and GAE, cutaneous, sinus, lymph nodes, thyroid, and
adrenals (n=1; case 2). Other disseminated cases included: cutaneous, lungs, and keratitis
(n=1; case 7); cutaneous, lungs, heart, kidney, spleen, and lymph nodes (n=1; case 16);
cutaneous, sinus, and osteomyelitis (n=1; case 18); cutaneous, liver, and bronchoaveolar
lavage (n=1; case 23). One case reported sinus and lung involvement (case 25).
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The majority of the disseminated acanthamoebiasis cases were in adult males
(n=18; cases 4-10, 13-15, 18, 19, 21, 22, 24-26, 29), and all children (<18 years of age)
reported to have disseminated acanthamoebiasis were boys (n=4; cases 1, 11, 16, 17).
Seven females were reported with disseminated disease (cases 2, 3, 12, 20, 23, 27, 28).
Three reports noted that the patients were of Hispanic ethnicity (cases 2, 11, and 14)
although two additional cases were perhaps of Hispanic ethnicity (cases 6 and 28), being
described as Mexican American and Nicaraguan, respectively. However, the other 26
case reports failed to describe ethnicity, so an assessment of proportion of cases by
ethnicity cannot be made. Only two reports included information about possible
environmental exposures and they were both water exposures, one from fishing on a
freshwater lake (case 29) and one from wading in drainage ditches (case 1). When
timeframes were able to be determined, the number of days between suspected onset of
symptoms and death ranged from 8 to 765 days (cases 1-3, 5, 6, 8, 10-13, 16, 19-23, 25,
26, 29). Three cases resolved their infections and did not die (cases 17, 23, 24) and eight
did not have adequate information on the symptom onset/death timeframe to determine
outcome status (cases 4, 7, 9, 14, 15, 18, 27, 28). The number of days between
hospitalization and death ranged from 2 to 120 days (cases 1-7, 9, 10, 14, 15, 18, 25, 26,
27, 28). Twelve cases did not have adequate information on the hospitalization/death
timeframe (cases 7, 8, 11, 12, 13, 16, 17, 19, 20, 21, 22, 28). Prognosis for those
diagnosed with disseminated disease was poor, with 25 cases having died either from
Acanthamoeba infection or from other complications (cases 1-16, 18-21, 25-29). In one
case, it is unknown whether the patient survived (cases 22). Three cases were still living
at the time of the published report, with follow-ups of one month (case 24) and 12
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months (case 23). The third report did not give a timeframe but mentioned the patient was
still being maintained on therapy (case 17).
In contrast, only seven cases of disseminated Balamuthia have been reported.
[See Appendix A, Table 2 for all disseminated balamuthiasis case references.] The
information concerning potential health-related predisposing factors for these cases was
limited and varied, including a history of alcohol or drug abuse (n=3; cases 1, 2, 6), otitis
media (n=1, case 5), a history of a farm accident resulting in a contaminated wound and
subsequent limb amputation (n=1, case 3), and ankylosing spondylitis (n=1; case 4). One
case-patient had a history of coronary artery disease (case 7), but it is unclear whether
this medical condition was significant or not given that Balamuthia organisms were
found in the CSF and skin but nowhere else. Unlike acanthamoebiasis, all the
manifestations of disseminated balamuthiasis included GAE. The majority of cases were
GAE and cutaneous infections (n=4; cases 3, 4, 6, 7), and the rest were GAE with
infection of another organ outside the brain (n=3; cases 1, 2, 5).
As with disseminated acanthamoebiasis, the majority of cases of disseminated
balamuthiasis were in adult males (n=6; cases 1-4, 6, 7). Only one child was reported to
have this manifestation of illness and this case was female (case 5); this same case was
reported as being of Hispanic ethnicity and having a travel history to Mexico. Ethnicity
was reported in one other case (case 6, Hispanic), but the remaining 5 case-patients with
disseminated balamuthiasis had no ethnicity reported so no pattern can be determined
from these data. Environmental exposure history was limited with only two reports
providing information: both mentioned potential soil exposures (case 3, 4). When
timeframes could be determined, the number of days between suspected onset of
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symptoms and death ranged from 24 to 568 days (cases 1-3, 5-7). One case-patient
resolved his infection and did not die, but the case report did not provide adequate
information to determine the time period between symptom onset and resolution (case 4).
The number of days between hospitalization and death ranged from 13 to 77 days (cases
1-3, 5-7). Clinical outcomes for disseminated Balamuthia disease were also poor, with
six of the case-patients dying (cases 1-3, 5-7) and one reported survivor (case 4). This
patient was followed for more than five years and seemed to have recovered from his
infection.
Granulomatous amebic encephalitis (GAE)
There are 21 published reports of granulomatous amebic encephalitis caused by
Acanthamoeba spp. from 1955 to 2009. [See Appendix A, Table 3 for all Acanthamoeba
GAE case references.] Similar to the disseminated form of acanthamoebiasis, the most
common predisposing condition among infected patients was HIV/AIDS (n=4, cases 10,
11, 14, 20), and an equal number of patients with GAE had a history of substance and
alcohol abuse (n=4; cases 2, 3, 15, 21). Other potential predisposing health conditions
included: cancer (n=2) with long-term immunosuppression (case 5) and with a stem cell
transplant (case 16); organ transplantation (n=2) with immunosuppressive therapy (cases
17) and with diabetes (case 19); lupus (n=2; case 18), where one case-patient was also
dependent on drugs and alcohol and counted above as having history of substance abuse
(case 21); mixed connective tissue disorder (n=1; case 9); and pneumonitis (n=1, case 6).
One case-patient (case 4) had a stroke, but it is unknown if this may be a predisposing
condition. Of the 21 reports, five had either unknown or unpublished health conditions
(cases 1, 7, 8, 12, 13) that may have made them more susceptible to infection.
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The majority of cases of Acanthamoeba GAE were adult males (n=13; cases 2-5,
10-15, 17, 19, 20). Only three cases were in children under the age of 18, and all of them
were female (cases 1, 7, 8). There were five adult females with Acanthamoeba GAE
(cases 6, 9, 16, 18, 21). No case reports noted patients of Hispanic ethnicity. Two
reports noted that case-patients had water exposures; one case-patient was exposed to
water that had accumulated in a basement (case 3), but the source of the water was not
specified, and the other case-patient frequently used swimming pools for therapy after a
cerebrovascular accident (case 4). A third case-patient, a male, had multiple exposures,
including a potential occupational exposure (general contractor) and exposures to water
and soil. He played volleyball on sand courts and also gardened as a hobby. He also
enjoyed fishing and was on a trip approximately one month prior to his illness onset,
although he denied direct water contact (case 19). The remaining 18 case reports did not
comment on potential environmental exposures. When timeframes could be determined,
the number of days between suspected onset of symptoms and death ranged from 8 to
252 days (cases 1, 5, 6, 9, 10, 11, 14-21). Seven did not have adequate information on
the symptom onset/death timeframe (cases 2-4, 7, 8, 12, 13). The number of days
between hospitalization and death ranged anywhere from 4 to 63 days (cases 1, 2, 3, 5, 9,
10, 11, 14, 16, 17, 21). Ten cases did not have adequate information on the
hospitalization/death timeframe (cases 4, 6-8, 12, 13, 15, 19, 20). Among cases where
the clinical outcome was known, fatality was 100% (cases 1-7, 9-11, 14-21). Three cases
had unknown outcomes (cases 8, 12, 13).
Thirty-nine cases of Balamuthia GAE in the United States have been published in
case reports or cited in summary compilations. [See Appendix A, Table 4 for all
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Balamuthia GAE case references.] Eleven case reports did not include information that
lent evidence of predisposing health factors, nor was the patient’s status stated as being
healthy (cases 3, 4, 6, 9, 23-25, 30, 31, 35, 36). Nine cases were reported as being
previously healthy before becoming ill (cases 7, 10, 12, 13, 15, 20, 21, 27, 32). In
instances where predisposing health factors were known, nine cases had otitis,
pharyngitis, or some other type of respiratory illness (cases 2, 5, 11, 14, 18, 19, 22, 33,
37). Five cases had a history of alcohol or drug abuse (cases 5 [also had TB as noted
above], 8, 17, 26, 29,). Other predisposing health factors included: organ transplantation
and immunosuppressive therapy (cases 34, 38, 39), HIV (case 16), prolonged steroid use
(case 28), and diabetes (case 1).
Unlike Acanthamoeba GAE, the majority of cases of Balamuthia GAE were in
males younger than the age of 18 years (n= 14; cases 2, 3, 9, 13-15, 18, 23, 24, 28, 30,
32, 36, 37) followed by adult males (n= 11; cases 5, 6, 8, 17, 25, 26, 29, 31, 33, 35, 39).
There were eight case reports on females under age 18 (cases 4, 7, 10-12, 20-22) and five
adult women (cases 1, 16, 19, 27, 38). One case report did not include any age or gender
information (case 34). Fourteen of the cases (cases 7, 10, 15, 17, 21-25, 28-31, 36) were
reported to be of Hispanic ethnicity; the rest of the case reports did not include
information on ethnicity. Environmental exposure to soil was cited in six cases (cases 7,
25, 27, 30, 33, 35). Two patients cited gardening as a hobby (cases 27, 35), two had an
occupational exposure to soil (case 25, 33), one cited motorcycling in the desert as a
hobby (case 30), and one visited a farm (case 7). One case-patient had a history of
frequent outdoor play in soil as well as exposure to an untreated well-water source for
recreation and drinking (case 37). Three additional cases cited water exposure, one to a
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freshwater pond (case 20), one to well water (case 1), and one to a lake (the latter may
have also had soil exposure as the child of a migrant farmer, case 9). When timeframes
were able to be determined, the number of days between suspected onset of symptoms
and death ranged from 8 to 240 days (cases 1-5, 7, 10, 12-15, 17-19, 22, 24, 25, 33, 37,
38). Five cases resolved their infections and did not die (cases 21, 27, 31, 32, 39) and
fourteen did not have adequate information on the symptom onset/death timeframe (cases
6, 8, 9, 11, 16, 20, 23, 26, 28, 29, 30, 34, 35, 36). The number of days between
hospitalization and death ranged anywhere from 3 to 120 days (cases 1, 2, 9, 11, 16, 20,
26, 28-30, 35, 36). Twenty-two cases did not have adequate information on the
hospitalization/death timeframe (cases 3-8, 10, 12-15, 17-19, 22-25, 33, 34, 37, 38).
Survival for those with Balamuthia GAE was slightly better for those with GAE caused
by Acanthamoeba spp. Four patients are reported to have survived (case 21, 27, 31, 39)
and the other 35 died (cases 1-20, 22-26, 28-30, 32-38).
Cutaneous acanthamoebiasis
Twelve cases of cutaneous acathamoebiasis occurring in the United States have
been reported in the literature and all cases were among immunocompromised adults.
[See Appendix A, Table 5 for all cutaneous acanthamoebiasis case references.] The main
predisposing medical condition was HIV/AIDS (n=10; cases 1-4, 6-11). The only other
condition cited in the literature was immunosuppression due to organ transplantation
(n=2; cases 5, 12). Nine of the case-patients were males (cases 1-7, 9, 10) and three were
females (cases 8, 11, 12). Two case reports noted that the patients were of Hispanic
ethnicity (cases 2, 8), but ethnicities were not reported for the other 10 case-patients. No
soil exposures were cited in the case reports, although two reports noted cases had
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freshwater exposure before skin lesions appeared (cases 6, 7). One case was noted to
have a local creek nearby that was used as a domestic drinking water source (case 12).
No potential environmental exposures were cited for the remaining nine case-patients.
When timeframes could be determined, the number of days between suspected onset of
symptoms and death ranged from 22 to 450 days (cases 1-4, 6, 8-11). Two cases
resolved their infections and did not die (cases 5, 12) but the symptom onset/death
timeframes could not be determined and one fatal case did not have adequate information
on the symptom onset/death timeframe (case 7). The only report of number of days
hospitalized was in a survivor who was hospitalized for approximately 150 days (case
12). The remaining cases did not have adequate information on the hospitalization/death
or hospitalization/discharge timeframes (cases 1-11). There were three reported
survivors of cutaneous Acanthamoeba (cases 5, 11, 12) and the other nine cases resulted
in death (cases 1-4, 6-11).
Acanthamoeba rhinosinusitis
Two cases of Acanthamoeba rhinosinusitis have been reported in the literature.
[See Appendix A, Table 6 for all Acanthamoeba rhinosinusitis case references.] Both
patients were immunocompromised adults, one male (case 1) and one female (case 2).
The male had HIV and recurrent sinus problems and the female had undergone a bilateral
lung transplantation due to a progressive lung disease. Both of these patients are reported
to have resolved their infections at 4 (case 1) and 3 (case 2) weeks respectively, but no
further follow-up was mentioned in either article.
Acanthamoeba osteomyelitis
A lone case of Acanthamoeba osteomyelitis was reported in 1981 in a 32-year-old

16
pre-diabetic woman. [See Appendix A, Table 7 for all Acanthamoeba osteomyelitis case
references.] She had a mass in the right mandibular area, which was removed and
replaced with a bone graft. A subsequent surgery was necessary in order to remove
necrotic bone. Inflammatory exudate from bone marrow in the necrotic bone was
positive for Acanthamoeba. The report does not cite any follow-up after the patient’s
surgery for necrotic bone removal, so it is not known if she continued to improve and
remain ameba-free (case 1). Three other cases of Acanthamoeba osteomyelitis have been
reported in the literature, but all of these case patients had disseminated Acanthamoeba
infection (see Appendix A, Table 1, cases 17, 18, 27).
Survivors: Acanthamoeba
There have been nine reports of successful treatment of acanthamoebiasis: three
disseminated (Appendix A, Table 1, cases 17, 23, 24), three cutaneous (Appendix A;
Table 4, cases 5, 11, 12), two rhinosinusitis (Appendix A, Table 5, cases 1, 2), and one
osteomyelitis (Appendix A, Table 6, case 1). There have been four published cases
where the clinical outcome was unknown due to lack of information in the reports: one
was a disseminated disease case (Appendix A, Table 1, case 22) and three were GAE
cases (Appendix A, Table 3, cases 8, 12, 13). In 1998, a report was published of a 7year-old male with HIV who had been diagnosed with cutaneous Acanthamoeba disease
at 5 ½ years of age (Appendix A, Table 1, case 17). Initially this case-patient was treated
with fluconazole without complete resolution of his skin lesions. Several months after
his diagnosis of cutaneous Acanthamoeba disease, he had a painful thumb and testing
showed osteomyelitis without a definitive cause. He was given pentamidine daily over
the course of a month and then maintained on itraconzole with monthly treatments of
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pentamidine. By the time he was 6-years-old, he was diagnosed with granulomatous
amebic osteomyelitis after presenting with a swollen elbow. He was again given
pentamidine daily for one month. His cutaneous lesions and osteomyelitis recurred when
he was close to 7 years old, despite maintenance therapy. Daily pentamidine for one
month was given in combination with 5-fluorocytosine (5-FC). The child was then
maintained on 5-FC and antiretroviral treatment and was alive at the time of publication
but had occasional new skin lesions.
In 1999 a report was published of a 39-year-old woman who had undergone a
lung transplant six years earlier (Appendix A, Table 1, case 23). She was reported to
have presented with skin nodules, with new nodules continuing to develop over the next
several days. Multiple biopsies were performed before a diagnosis of Acanthamoeba was
finally made. Initial treatment included a combination of 5-FC and pentamidine, as well
as topical treatment with chlorhexidine gluconate and ketoconazole cream. Upon going
into respiratory failure and requiring mechanical ventilation, the patient’s
bronchoalveolar lavage (BAL) was found to be positive for Acanthamoeba. At this point
azithromycin was added to her drug regimen and it appears she stayed on this regimen for
close to a month, at which time her skin lesions were improving and her BAL was
negative. However, she began to have side effects that resulted in several of the
medications being discontinued. The patient had abnormal liver function tests and a
biopsy showed Acanthamoeba was present in this organ, so the patient was given lower
doses of pentamidine and 5-FC was restarted. On discharge, the patient was still being
treated with 5-FC and clarithromycin was added. The woman showed no evidence of
infection 12 months after her hospital discharge.
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In 2002, a 37-year-old AIDS and cancer patient was reported to have nasal
obstruction that did not resolve with antibiotic treatment (Appendix A, Table 1, case 24).
He subsequently developed papular lesions on his extremities. Multiple biopsies were
inconclusive, although Cytomeglovirus was suspected and treatment was begun; the
patient did not respond well. Subsequently, the nasal obstruction became worse until the
patient needed surgery, at which point a diagnosis of Acanthamoeba was made from the
specimens obtained during surgery. The patient was given pentamidine and topical
treatments of both chlorhexidine and ketoconazole. When he had side effects due to
pentamidine it was discontinued and 5-FC was begun; this regimen was continued for a
month with successful resolution of his disease. At the time of the report, the patient was
still taking itraconazole but there was no evidence of recurrence. The report does not
mention when treatment with this drug was begun.
Three cases of cutaneous acathamoebiasis were reported to have survived. In
1992, a 31-year-old man who had undergone a kidney transplant presented with skin
nodules (Appendix A, Table 5, case 5). Upon diagnosis of Acathamoeba via positive
skin biopsies, he was given intravenous (IV) pentamidine and topical treatment with
chlorhexidine and ketoconzaole. He was treated with pentamidine for 4 weeks, although
the dosage had to be reduced due to an elevated creatinine level. At discharge from
hospital, his previous medications were discontinued and he was then treated with oral
itraconazole. He continued to take this medicine at a reduced dosage for at least two
years after his diagnosis without recurrence of infection.
In 2004, a 51-year-old woman with AIDS presented with skin papules,
photophobia, and headache (Appendix A, Table 5, case 11). Based on a skin biopsy, she

19
was diagnosed with cutaneous Acanthamoeba disease and underwent a CT scan and
lumbar puncture, which were subsequently negative for evidence of central nervous
system involvement. Her treatment regimen included pentamidine and 5-FC, but new
skin nodules continued to appear so sulfadiazine and highly active antiretroviral
treatment (HAART) were added. After 14 days of pentamidine once a day, penatmidine
was discontinued and the patient was continued on maintenance therapy of 5-FC,
sulfadiazine, and HAART. The patient was still free of CNS involvement 3 months after
release from the hospital with slow improvement of her skin lesions, possibly due to
inconsistent compliance with her treatment.
Also in 2004, a 52-year-old woman who had a lung transplant three years earlier
and remained on immunosuppressive therapy presented with nodules on her trunk and
lower extremities (Appendix A, Table 5, case 12). She was diagnosed with cutaneous
Acanthamoeba disease and unsuccessfully treated with itraconazole and metronidazole
for two weeks. CDC and an infectious disease specialist were consulted and the woman
was started on IV amphotericin B lipid complex and voriconazole. She was discharged
on the same medications delivered through an outpatient service. Her treatment with
these two drugs lasted 10 weeks before the dosage and frequency were changed and IV
voriconzole was switched to oral voriconazole. After her discharge she was maintained
on oral voriconazole for 5 months with resolution of her skin lesions and no recurrence.
Two cases of Acanthamoeba rhinosinusitis were reported to have survived their
infections. A 45-year-old man with HIV had sinus difficulties over the course of a year
which necessitated multiple sinus surgeries before he was finally diagnosed with
Acanthamoeba rhinosinusitis (Appendix A, Table 6, case 1). He had a subtotal
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septectomy, used gentamycin nasal rinses for 4 weeks and was maintained on oral
itraconazole. No timeframe was given for the maintenance therapy, nor was the time
frame between the resolution of the infection and the publication of the paper given. In
2005, a 49-year-old woman who had undergone a lung transplant was reported to have
survived Acanthamoeba rhinosinusitis (Appendix A, Table 6, case 2). Seven months
after transplantation she had sinus difficulties and after diagnosis was treated with
amphotericin, voriconazole, and caspofungin. Three weeks after treatment began she
underwent a sinus debridement, but no Acanthamoeba were seen in specimens from this
debridement: she remained Acanthamoeba free in the month following which is as long
as the report states the patient was followed.
The only other published report of an Acanthamoeba survivor was in 1981
(Appendix A, Table 7, case 1). A 32-year-old female was diagnosed with amebic
osteomyelitis after a sequestrum of necrotic bone was removed from her jaw. The patient
does not appear to have been treated with drugs that were specific to resolving
Acanthamoeba infections. She was given IV penicillin, used betadine mouthwash after
surgery, and was discharged. The authors do not discuss long-term follow up, but as she
was reported as still alive at the time of the published report she is counted among the
survivors in this review. As with many of these cases where patients were reported to
have survived, it is difficult to determine if there were later recurrences or if patients truly
resolved their infections and never relapsed.
Survivors: Balamuthia
There have been six reports of successful treatment of balamuthiasis, one with
disseminated disease (Appendix A, Table 2, case 4) and five with Balamuthia GAE
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(Appendix A, Table 4, cases 21, 27, 31, 32, 39). A 64-year-old man who previously had
a skin lesion that was biopsied with pending results presented with neurological
difficulties (Appendix A, Table 2, case 4). Lesions were seen in the parietal area of his
brain on both a CT scan and a MRI. He subsequently underwent a brain biopsy and was
released 10 days later. He was then re-hospitalized and received a diagnosis of B.
mandrillaris disseminated disease as Balamuthia organisms were identified in both the
brain tissue and the skin biopsy. He was treated with 5-FC, fluconazole, IV pentamidine,
sulfadiazine, and azithromycin (which was later switched to clarithromycin). The patient
was ventilated and in intensive care for seven weeks. He was discharged to a
rehabilitation unit and fluconazole was discontinued. Following a relapse, fluconazole
was added again and he was maintained on fluconazole and sulfadiazine over the course
of five years. The patient did recover enough to be able to walk, perform activities of
daily living and communicate well.
There have been five reports of survivors who were diagnosed with Balamuthia
GAE. Three of the case-patients were reported as previously healthy (Appendix A, Table
4, cases 21, 27, 32) and one had an unknown health status (Appendix A, Table 4, case
31). A report published in 2003 discusses a 5-year-old girl who, 48 days after initial
presentation, was diagnosed with Balamuthia GAE (Appendix A, Table 4, case 21). The
patient underwent several combinations of treatment. Initially she was treated with
ketoconazole and metronidazole for 34 days. These medications were then discontinued
and she was placed on clarithromycin and flucytosine for 14 days. Her treatment was
subsequently changed again and included azithromycin, fluconazole, pentamidine, and
thioridazine. Over the course of the next two-and-a-half years, her treatment varied,
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primarily because of discontinuation of medications due to side effects and initiation of
medicines due to seizures. More than two-and-a-half years after her first hospital
admission she was still maintained on clarithromycin and fluconazole.
In 2004, a report was published of a 72-year-old woman who underwent a brain
biopsy that was positive for Balamuthia (Appendix A, Table 4, case 27). The biopsy was
excisional, and upon diagnosis, the patient was treated with pentamidine (IV),
sulfadiazine, fluconazole, and clarithromycin. The patient remained asymptomatic, but it
is unknown how much time elapsed between the case and the published report as well as
how long she was maintained on therapy. In 2007 a Balamuthia GAE survivor was
reported (Appendix A, Table 4, case 31). The report only stated that the patient was
living at the time of his last report to a physician, but he was lost to follow-up.
In 2010, a report of a 2-year-old boy with GAE was published (Appendix A,
Table 4, case 32). He was initially treated for tuberculosis but underwent a biopsy and
was given a diagnosis of Balamuthia. He was treated with pentamidine, fluconazole,
flucytosine, sulfadiazine, clarithromycin, and thioridazine. The boy was placed on a
ventilator and required a ventriculoperitoneal shunt. He was maintained on a ventilator
for almost two months and then transferred to a rehabiliation unit. Over the course of at
least 22 months, the case-patient was given clarithromycin, sulfadiazine, flucytosine, and
fluconazole without evidence of an active infection. After time in the rehabilitation unit,
the boy was able to follow simple commands, had improved postural stability, and was
attempting to speak. MRIs show that the lesions decreased in size and number.
The most recent report of a Balamuthia GAE survivor was published in 2010
(Appendix A, Table 4, case 39). A kidney transplant recipient who acquired his infection
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through organ transplantation from an infected donor survived the infection, although he
spent two months in a coma. He slowly regained cognitive and motor functions and
entered a rehabilitation unit. He had residual neurologic effects such as right arm
paralysis and bilateral leg weakness. He also had intermittent vision loss. No treatment
regimen was included in the publication.
Ethnicity
In 2004, a letter to the editor of Emerging Infectious Diseases was published,
suggesting that Hispanic ethnicity may be a risk factor for Balamuthia GAE.20 The
primary authors of this letter were involved with the California Encephalitis Project
(CEP), which was begun in 1998 with the purpose of assisting clinicians in the State with
cases of encephalitis by offering enhanced diagnostic testing for infectious agents. The
CEP collects serum and other samples from patients in California that have presented
with encephalitis, and a subset of these samples were pulled for Balamuthia screening.
The criteria for screening included: case history that had clinical or laboratory
information suggestive of Balamuthia GAE and either an outdoor occupational exposure
or other outdoor recreational activity that might have lead to exposure to soil. Of 215
samples tested, three were positive for Balamuthia. Four additional samples, not a part of
the CEP, were also tested and were found to be positive. All seven cases were healthy
Hispanic Americans who died of GAE. The CEP contacted CDC to obtain information
about their records of Balamuthia cases, and it was determined that based on either case
report identification of ethnicity or a traditional Hispanic last name, about 50%, or 25, of
the U.S. case patients with known or suspected ethnicity were Hispanic Americans. No
information was given on the number of cases with truly unknown ethnicities, just that
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there were approximately 50 U.S. cases at the time of publication. This same letter also
stated that 36% of Balamuthia GAE cases occurred in Latin American countries.20

CHAPTER III: METHODS AND PROCEDURES
CDC’s Free-Living Ameba (FLA) Laboratory collects information on cases of
suspected Balamuthia and non-keratitis Acanthamoeba diseases as part of their contact
with physicians and laboratorians who are seeking assistance with diagnosis. The head of
the FLA Laboratory, Dr. Govinda Visvesvara, has been working with free-living amebae
since 1964 and has been with the FLA Laboratory since 1974. He was the first scientist
to isolate and subsequently name Balamuthia mandrillaris and is considered one of the
world’s FLA experts, with more than 250 publications on the subject. The FLA
Laboratory is one of the only research laboratories in the United States performing
reference diagnostic testing for free-living amebae, and the lab handles specimens tested
through various methods such as staining of histopathologic slides, culture, and
polymerase chain reaction (PCR). The FLA Laboratory is one of only two known labs
currently performing an antibody test (indirect immunofluorescence or IIF) for the freeliving amebae; the other laboratory is at the California Department of Health Services,
which runs the California Encephalitis Project (CEP). These two labs have historically
shared data. Therefore, the FLA Laboratory holds records for most of the nonAcanthamoeba keratitis and Balamuthia mandrillaris FLA cases diagnosed in the United
States. It is for this reason that a review of FLA laboratory records supplemented with a
review of the published literature should capture the majority of FLA cases diagnosed in
the United States, even though diseases associated with the free-living amebae are not
nationally notifiable.
Data for this study were abstracted onto case report forms from CDC laboratory
25
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and clinical consultation files for positive cases of Balamuthia and non-keratitis
Acanthamoeba that occurred in the United States. See Appendix B for a copy of the case
report form. Data in the files ranged greatly in content from laboratory specimen
submission forms with little information about the patient’s clinical course to copies of
extensive medical records and autopsies.
A literature review was also performed to collect all published cases and media
reports of Balamuthia and non-keratitis Acanthamoeba disease occurring in the U.S. The
published cases were then compared to the CDC-diagnosed cases to determine which
ones referred to the same patients. This was done in three ways: matching similar patient
clinical and laboratory data, matching authors with contact clinicians or laboratorians,
and consultating with Dr. Govinda Visvesvara, the aforementioned head of the FLA
Laboratory. Information from published case reports took precedence over CDC records
when there was conflicting data, unless the publication conflicted with a final autopsy
report in CDC files. CDC records took precedence over any information found in the
general media. In instances where there was information on length of time but not
specific dates for illness onset, hospitalization, and/or time from illness onset to death,
dummy dates were entered for the purpose of calculating durations.
In instances where published cases could not be matched with CDC cases, the
diagnostic methods for the published cases were reviewed. Cases tested by the following
agencies/individuals were considered to be reputable cases based on their known
diagnostic methods: the California Department of Health Services; Dr. Eddy Willaert,
Institute of Tropical Medicine in Antwerp, Belgium; Dr. Julio Martinez, University of
Pittsburgh; Dr. Bruce Torian, Idaho; Dr. Gregory Booten, Ohio State University. If it
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was not apparent that a published case was in CDC records, or if one of the laboratories
above was not cited, individual cases were discussed with Dr. Visvesvara to determine if
he was familiar with the case. Diagnostic and clinical features of the published case were
reviewed to determine if the case likely fit a diagnosis of acanthamoebiasis or
balamuthiasis.
Each case-patient identified from these records and/or the literature review was
assigned a unique identifier consisting of a prefix of AC for Acanthamoeba or BA for
Balamuthia, followed by a two digit number representing the calendar year in which the
case first presented with symptoms (when known) or was either first reported to CDC or
published in the literature. A case number in sequential order from 001 to infinity was
designated as the last three digits of the unique identifier. Case information was then
entered into a limited-user database that serves as a resource for CDC clinical
consultation and surveillance.
The database has 976 variables and contains both quantitative and qualitative
data. A major issue with the database is that many of the variables are set up as
true/false, complicating the calculation of denominators for certain areas of data. The
database allows exportation of files in Excel format and splits the database information
into eight separate files when exporting: demographics, exposure history, medical
history, current illness, laboratory tests, histopathology, diagnostic imaging, and
diagnostic and treatment outcomes. For the purposes of this study, the information was
stripped of identifiers prior to analysis. The data were then analyzed using SPSS.
Exported data were split into separate files for Acanthamoeba and Balamuthia.
Each of the eight database files for each organism were imported into SPSS, labeled and
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assigned type, values, and measures. All eight files were also combined for each
organism for instances where information in the separate databases needed to be
examined together. Data were first explored by examination of frequencies, ranges and
means, and cross tabulations. Research question 1 was answered using these methods,
and frequencies, ranges, and means were used for research question 4. For research
question 2, frequencies were also used, but because acanthamoebiasis has so many
manifestations, it was useful to explore the data by disease manifestation. Therefore,
case summaries were run using final diagnosis as the grouping variable and presenting
symptoms in the variables column. Research question 3 was also examined using case
summaries with the survived variable as the grouping variable and treatment drugs in the
variables column. Medications given to the survivors were visualized using Excel
spreadsheets to determine commonalities in the drugs used and duration. Although the
methods used above answered the research questions, I also further analyzed some of the
demographic, exposure history, previous medical history, and outcomes data to try to
glean further information about these diseases and produced epidemologic curves for all
reported cases of acanthamoebiasis and balamuthiasis in the United States through 2009.

CHAPTER IV: RESULTS
A total of 114 cases of acanthamoebiasis was analyzed; 65 (57%) of these cases
had some information about them published in the literature. Similarly, 70 cases of
balamuthiasis were analyzed; 46 (66%) of these cases had some information about them
published in the literature. Cases of acanthamoebiasis occurred between 1955 and 2009
(Figure 1); cases of balamuthiasis occurred between 1974 and 2009 (Figure 2). See
Appendix C for larger versions of these figures.
Figure 1: Epidemic Curve for Cases of Non-Keratitis Acanthamoeba spp.—United
States, 1955-2009

29

30
Figure 2: Epidemic Curve for Cases of Balamuthia mandrillaris—United States,
1974-2009

Demograhics: Research Question 1
Little information was available about the race and ethnicity of Acanthamoeba
cases. Sixty-two percent of the race data were missing (n=43/114). Among the 43 case
patients who had data available, the racial breakdown was: 63% white (n=27/43), 35%
African American (n=15/43), and 2% American Indian (n=1/43). Ninety percent of the
data were missing for the ethnicity variable (n=11/114), but among the known cases 82%
(n=9/11) were Hispanic and 18% (n=2/11) were non-Hispanic. Five out of the nine
known Hispanics were treated in the state of California. Immigration data were also
limited; 93% of the data were missing (n=8/114), but when known 75% had immigrated
to the United States (n=6/8) and 25% were natural U.S. residents (n=2/8). There was no
particular country of emigration in common among those six cases who had immigrated.
Four percent of cases were missing data for the age variable (n=110/114). Ages of cases
ranged from a minimum of 8 months old to a maximum of 79 years old, with a mean of
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38.8 years of age; 7% (n=8/110) were children younger than 18 years of age, 87%
(n=96/110) were adults 18-64 years of age, and 6% (n=6/110) were 65 years of age or
older. Males were 73% of cases (n=82/112) and females were 27% (n=30/112); two
cases had missing information. See Figure 3 for an epidemic curve by age of
Acanthamoeba spp. [Appendix C has a larger version of this figure.] Also see Figure 4
for the geographic distribution of Acanthamoeba spp. cases by state of treatment.
Figure 3: Epidemic Curve by Age for Cases of Acanthamoeba spp.—United States,
1955-2009

Figure 4: Geographic Distribution of Non-Keratitis Acanthamoeba spp. Cases by
State of Treatment
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Limited data were available for race, ethnicity, and immigration status for
Balamuthia cases. Fifty-three percent of the race data were missing (n=33/70). Among
cases where data were available, the racial breakdown was: 58% white (n=19/33), 36%
African American (n=12/33), and 6% Asian/Pacific Islander (n=2/33). Fifty-nine percent
of the data were missing for ethnicity (n=29/70), but among the known cases 76% were
Hispanic (n=22/29) and 24% were non-Hispanic (n=7/29). Twelve of the 22 known
Hispanic case-patients were treated in the state of California. The immigration variable
had 84% of the data missing (n=11/70); 36% of case-patients with known immigrantion
status immigrated to the U.S. (n=4/11) and 64% were natural residents of the U.S.
(n=7/11). Immigrants most commonly came from Mexico (75%, n=3/4). Two cases
were missing data for the age variable, with ages ranging from a minimum of 4 months to
a maximum of 89 years of age, and a mean age of 30.4 years; 43% (n=29/68) were
children younger than 18 years of age, 47% (n=32/68) were adults 18-64 years of age,
and 10% (n=7/68) were 65 years of age or older. Males were 65% of cases (n=45/69)
and females were 35% (n=24/69); only one case was missing gender information. See
Figure 5 for an epidemic curve by age of Acanthamoeba spp. [Appendix C has a larger
version of this figure.] Also see Figure 4 for the geographic distribution of Balamuthia
mandrillaris cases by state of treatment.
Figure 5: Epidemic Curve by Age for Cases of Balamuthia mandrillaris—United
States, 1974-2009
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Figure 6: Geographic Distribution of Balamuthia mandrillaris Cases by State of
Treatment

Table 1: Summary of Demographic Data for Non-Keratitis Acanthamoeba spp. and
Balamuthia mandrillaris Cases
Variable
Acanthamoeba (N=114)
Balamuthia (N=70)
Data
Missing
Data
Missing
Race
White
63% (27/43)
58% (19/33)
62%
African American
35% (15/43)
36% (12/33) 53%
(71/114)
(37/70)
American Indian
2% (1/43)
0% (0/33)
Asian/Pacific Islander 0% (0/43)
6% (2/33)
Ethnicity
Hispanic
82% (9/11)
90%
76% (22/29) 59%
(103/114) 24% (7/29) (41/70)
Non-Hispanic
18% (2/11)
Immigration Immigrant
75% (6/8)
93%
36% (4/11) 84%
(106/114) 64% (7/11) (59/70)
Non-Immigrant
25% (6/8)
Age
Range
8 m–79 y
4%
4 m–89 y
3%
(4/114)
(2/70)
Mean
38.8 years
30.4 years
Sex
Male
73% (82/112) 2%
65% (45/69) 1%
(2/114)
(1/70)
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Presenting Symptoms: Research Question 2
Patients presented with a variety of non-descriptive symptoms for both
Acanthamoeba and Balamuthia disease. Fever and headache were the two most common
symptoms shared by those with either disease. See Tables 2 and 3 for the top ten
symptoms patients presented with upon examination or hospitalization for illness caused
by Acanthamoeba spp. and Balamuthia mandrillaris respectively.
Table 2: Top Ten Presenting Symptoms of Patients Later Diagnosed With NonKeratitis Acanthamoeba spp. Infection (N=95/114)
Presenting Symptom
No. of Cases Reporting Symptoms
Other General Symptoms*
39
Fever
34
Headache
29
Sinus problems
18
Other Neurologic Deficit**
17
Lethargy/Fatigue
13
Confusion
9
Weight Loss
8
Weakness
7
Altered Mental Status
6
Cough
6
Nausea
6
Vomiting
6
*Other general symptoms include but were not limited to: chills (n=7/39), facial
swelling/pain/tenderness (n=5/39), epitstaxis (n-=3/39), jaundice (n=2/39), night sweats
(n=2/39), and incontinence (n=2/39).
** Other neurologic symptoms include but are not limited to: Romberg’s sign (n=1/17),
Babinski sign (n=1/17), Kernig’s sign (n=1/17), Brudzinki’s sign (n=1/17).

Table 3: Top Ten Presenting Symptoms of Patients Later Diagnosed With
Balamuthia mandrillaris Infection (N=63/70)
Presenting Symptom
No. of Cases Reporting Symptoms
Fever
23
Headache
18
Lethargy/Fatigue
18
Vomiting
18
Other General Symptoms*
16
Other Neurologic Deficit**
15
Seizures
14
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Weakness
13
Other Visual Symptoms
11
Altered Mental Status
10
Hemiparesis
9
Ataxia
8
*Other general symptoms include but were not limited to: incontinence (n=3/16), neck
pain (n=2/16), and loss of appetite (n=2/16).
** Other neurologic symptoms include but are not limited to:Babinski sign (n=2/15, and
unresponsiveness (n=2/15).
Because both acanthamoebiasis and balamuthiasis have multiple disease
manifestations, a further exploration was done looking at presenting symptoms by disease
manifestation. Symptoms were broken up into four categories: general presenting
symptoms (17 variables), visual symptoms (4 variables), neurologic symptoms (29
variables), and skin lesions (4 variables). Cases that had no information for every
variable in a category were taken out of the frequency counts and treated as unknowns.
Remaining cases may have had more than one symptom in each of the four presenting
symptom categories. In the case of the skin lesions category, knowns included those
cases who indicated they had skin lesions or did not have skins lesions. After analysis it
was apparent that not all of the possible variables for the symptom categories were
selected as symptoms upon presentation. See Tables 4-7 for breakdowns of
Acanthamoeba cases; see table footnotes for numbers of variables not chosen in each
category.
Table 4: Presenting General Symptoms for Cases of Non-Keratitis Acanthamoeba
spp. Infection by Disease Manifestation
Disease Manifestation Presenting Symptom
No. of Known Cases
Reporting Symptoms
Disseminated
Other General Symptoms
19
(n=30/36)*
Fever
12
Sinus problems
11
Headache
10
Lethargy/Fatigue
5
Cough
4

36
Nausea
Weight Loss
Shortness of breath
Vomiting
Stiff Neck

3
3
2
1
1

GAE (n=25/48)*

Fever
Headache
Other General Symptoms
Lethargy/Fatigue
Vomiting
Nausea
Weight Loss
Diarrhea
Anorexia
Cough
Shortness of Breath
Sinus Problems

16
14
14
7
4
3
3
2
1
1
1
1

Cutaneous (n=10/23)*

Fever
Headache
Other General Symptoms
Diarrhea
Weight Loss
Myalgia
Sinus Problems
Shortness of Breath
Lethargy/Fatigue

5
3
4
2
2
2
2
1
1

Rhinosinusitis (n=4/6)* Sinus Problems
Fever
Headache
Other General Symptoms

4
1
1
1

Osteomyelitis (n=1/1)
Other General Symptoms
1
*Those reporting multiple general symptoms on initial presentation included: 19 GAE
cases, 24 disseminated cases, two rhinosinusitis cases, and six cutaneous cases.
Although it was possible to select up to 17 variables for presenting general symptoms,
three of those variables were not selected among those cases who reported presenting
symptoms.
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Table 5: Presenting Visual Symptoms for Cases of Non-Keratitis Acanthamoeba spp.
Infection by Disease Manifestation
Disease Manifestation Presenting Symptom
No. of Known Cases
Reporting Symptoms
Disseminated (n=3/36)* Blurred Vision
2
Diplopia
1
Other Visual Symptom
1
GAE (n=5/48)*

Blurred Vision
Diplopia
Other Visual Symptom
Photophobia

2
2
2
1

Cutaneous (n=2)
Photophobia
2
*Those reporting multiple visual symptoms on initial presentation included: two GAE
cases and one disseminated case.

Table 6: Presenting Neurologic Symptoms for Cases of Non-Keratitis Acanthamoeba
spp. Infection by Disease Manifestation
Disease Manifestation Presenting Symptom
No. of Known Cases
Reporting Symptoms
Disseminated
Confusion
5
(n=12/36)*
Other Neurologic Deficit
4
Weakness
3
Altered Mental Status
3
Behavioral Changes
1
Dysphagia
1
Hallucinations
1
Seizures
1
Hemiparesis
1
GAE (n=22/48)*

Other Neurologic Deficit
Weakness
Hemiparesis
Seizures
Confusion
Altered Mental Status
Aphasia
Ataxia
Numbness or Facial
Numbness
Hyperreflexia
Nystagmus

12
4
3
3
3
2
2
2
1
1
1
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Cutaneous (n=2/23)

Other Neurologic Deficit
1
Altered Mental Status
1
*Those reporting multiple neurologic symptoms included: 10 GAE cases and four
disseminated cases.
Although it was possible to select up to 29 variables for presenting neurologic symptoms,
15 of those variables were not selected among those cases who reported presenting
symptoms.

Table 7: Presenting Skin Lesions for Cases of Acanthamoeba spp. Infection by
Disease Manifestation
Disease Manifestation
Type of Skin Lesion
No. of Known Cases
Reporting Symptoms
Disseminated
Other Type
16
(n=34/36)*
Ulcers
7
Erythematous Nodules
6
No Skin Lesions
7
GAE (n=7/48)

Other Type
Ulcers
No Skin Lesions

3
1
3

Cutaneous (n=23/23)*

Other Type
Erythematous Nodules
Ulcers
Type Not Stated

9
7
5
4

Rhinosinusitis (n=2/6)

Ulcers
1
No Skin Lesions
1
*Those reporting multiple types of skin lesions on initial presentation included: four
disseminated cases and two cutaneous cases.
Although it was possible to select up to 4 variables for presenting skin lesions, one of
those variables were not selected among those cases who reported presenting symptoms.

Although the manifestations of balamuthiasis appear to be limited to GAE and
disseminated infection, which potentially have similar presenting symptoms, a
breakdown by disease manifestation and the same four presenting symptom categories
was done for cases of Balamuthia mandrillaris. This allows for an examination of any
similarities or differences in manifestations as well as a comparison to Acanthamoeba
GAE and disseminated disease. Balamuthia cases that had no information for any
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variable in a category were taken out of the frequency counts and treated as unknowns.
Remaining cases may have had more than one symptom in each of the 4 presenting
symptom categories. See Tables 8-11 for presenting symptoms of Balamuthia GAE and
disseminated balamuthiasis.
Table 8: Presenting General Symptoms for Cases of B. mandrillaris Infection by
Disease Manifestation
Disease Manifestation Presenting Symptom
No. of Known Cases
Reporting Symptoms
Disseminated (n=5/8)*
Headache
3
Nausea
2
Vomiting
2
Other General Symptoms
2
Fever
1
Diarrhea
1
Weight Loss
1
Stiff Neck
1
Disorientation
1
Lethargy/Fatigue
1
GAE (n=41/62)*

Fever
20
Vomiting
16
Headache
15
Lethargy/Fatigue
15
Other General Symptoms
14
Nausea
5
Anorexia
3
Stiff neck
2
Disorientation
2
Diarrhea
1
*Those reporting multiple general symptoms on initial presentation included: 25 GAE
cases and three disseminated cases.
Although it was possible to select up to 17 variables for presenting general symptoms,
four of those variables were not selected among those cases who reported presenting
symptoms.
Table 9: Presenting Visual Symptoms for Cases of B. mandrillaris Infection by
Disease Manifestation
Disease Manifestation Presenting Symptom
No. of Known Cases
Reporting Symptoms
Disseminated (n=1/8)
Other Visual Symptom
1
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GAE (n=13/62)*

Other Visual Symptom
10
Diplopia
4
Photophobia
1
*Those reporting multiple visual symptoms on initial presentation included: two GAE
cases.
Although it was possible to select up to 4 variables for presenting visual symptoms, one
of those variables were not selected among those cases who reported presenting
symptoms.

Table 10: Presenting Neurologic Symptoms for Cases of B. mandrillaris Infection by
Disease Manifestation
Disease Manifestation Presenting Symptom
No. of Known Cases
Reporting Symptoms
Disseminated (n=5/8)*
Other Neurologic Deficit
3
Hemiparesis
2
Seizures
2
Altered Mental Status
1
Aphasia
1
Confusion
1
Hallucinations
1
Weakness
1
GAE (n=48/62)*

Other Neurologic Deficit
12
Weakness
12
Seizures
12
Altered Mental Status
9
Ataxia
8
Hemiparesis
7
Behavioral Changes
6
Aphasia
5
Confusion
4
Cranial Nerve Deficit VI
3
Other Cranial Nerve
3
deficit
Cranial Nerve Deficit VII
2
Dysphagia
1
Facial Numbness
1
Hallucinations
1
Combativeness
1
Hyperreflexia
1
Loss of Balance
1
Nystagmus
1
Those reporting multiple neurologic symptoms on initial presentation included: 22 GAE
cases and five disseminated cases.
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Although it was possible to select up to 29 variables for presenting neurologic symptoms,
10 of those variables were not selected among those cases who reported presenting
symptoms.

Table 11: Presenting Skin Lesions for Cases of B. mandrillaris Infection by Disease
Manifestation
Disease
Type of Skin Lesion
No. of Known Cases
Manifestation
Reporting Symptoms
Disseminated
Other type
3
(n=4/8)
Ulcers
1
GAE (n=17/62)

Other type
3
No Skin Lesions
14
Although it was possible to select up to 4 variables for presenting skin lesions, two of
those variables were not selected among those cases who reported presenting symptoms.

In looking at a comparison of the top five presenting general symptoms for
disseminated acanthamoebiasis and balamuthiasis (Table 12), three of the top five were
the same. The differences were that disseminated acanthamoebiasis cases reported sinus
problems and lethargy/fatigue and disseminated balamuthiasis did not. But Balamuthia
cases experienced vomiting and nausea frequently enough to be in the top five general
symptoms. For presenting neurologic symptoms, the top five symptoms were similar for
both disseminated diseases but varied in that disseminated acanthamoebiasis cases
reported behavioral changes and dysphagia. Disseminated acanthamoebiasis cases
reported more visual symptoms more types of skin lesions than disseminated
balamuthiasis cases.
Table 12: Comparison of Top Five Presenting Symptoms for Disseminated
Acanthamoeba and Balamuthia Disease
General Symptoms
Acanthamoeba (n=30/36)
Balamuthia (n=5/8)
Presenting
No. of Known
Presenting
No. of Known
symptom
Cases Reporting symptom
Cases Reporting
Symptoms
Symptoms
Other General
19
Headache
3
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Symptoms
Fever
Sinus Problems
Headache

12
11
10

Lethargy/Fatigue

5

Nausea
Vomiting
Other General
Symptoms
Fever

2
2
2
2

Neurologic Symptoms
Acanthamoeba (n=12/36)
Balamuthia (n=5/8)
Confusion
5
Other
3
Neurologic
Symptom
Other Neurologic
4
Hemparesis
2
Symptom
Weakness
3
Seizures
2
Altered Mental
3
Altered Mental
Each symptom had
Status
Status, Aphasia, a count of 1
Confusion,
Hallucinations,
Weakness
Behavioral
Each symptom
Changes,
had a count of 1
Dysphagia,
Hallucinations,
Seizures,
Hemiparesis
Visual Symptoms
Acanthamoeba (n=3/36)
Balamuthia (n=1/8)
Blurred Vision
2
Other Visual
1
Symptom
Diplopia
1
Other Visual
1
Symptom
Skin Lesions
Acanthamoeba (n=34/36)
Other Type
16
Ulcers
7
Erythematous
6
Nodules
No Skin Lesions
7

Balamuthia (n=4/8)
Other Type
3
Ulcers
1
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In comparing the top five presenting general symptoms for Acanthamoeba and
Balamuthia GAE (Table 13), four of the five were the same. The only difference was
that Acanthamoeba GAE cases reported nausea, whereas Balamuthia GAE cases reported
vomiting. The presenting neurologic symptoms also differed somewhat, with 3 of the 5
being the same, but Acanthamoeba GAE cases reported hemiparesis and confusion,
whereas Balamuthia GAE cases indicated having altered mental status and ataxia.
Acanthamoeba GAE case-patients reported blurred vision where as Balamuthia GAE
case-patients did not; Balamuthia GAE case-patients reported a high number of other
visual symptoms. Both had reports of skin lesions but they were not diagnosed as
cutaneous disease manifestations of Acanthamoeba or Balamuthia.
Table 13: Comparison of Top Five Presenting Symptoms for Acanthamoeba and
Balamuthia GAE
General Symptoms
Acanthamoeba (n=25/48)
Balamuthia (n=41/62)
Presenting
No. of Known
Presenting
No. of Known
symptom
Cases Reporting symptom
Cases Reporting
Symptoms
Symptoms
Fever
16
Fever
20
Headache
14
Vomiting
16
Other General
14
Headache
15
Symptom
Lethargy/Fatigue
7
Lethargy/Fatigue 15
Nausea
4
Other General
14
Symptom
Neurologic Symptoms
Acanthamoeba (n=22/48)
Balamuthia (n=48/62)
Other Neurologic
12
Other Neurologic 12
Symptoms
Symptoms
Weakness
4
Weakness
12
Hemiparesis
3
Seizures
12
Seizures
3
Altered Mental
9
Status
Confusion
3
Ataxia
8
Visual Symptoms
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Acanthamoeba (n=5/48)
Blurred Vision
2
Diplopia
Other Visual
Symptom
Photophobia

2
2

Balamuthia (n=13/62)
Other Visual
10
Symptom
Diplopia
4
Photophobia
1

1
Skin Lesions

Acanthamoeba (n=5/48)
Other Type
3
Ulcers
1
No Skin Lesions
3

Balamuthia (n=13/62)
Other Type
3
No Skin Lesions
14

Treatment: Research Question 3
The survivors of Acanthamoeba infection were cases whose disease
manifestations were cutaneous, rhinosinusitis or disseminated infection, typically
involving skin and sinuses. There has not been a reported case of Acanthamoeba GAE,
or disseminated acanthamoebiasis with GAE involvement, that has survived. Among the
survivors of Acanthamoeba disease of those with known outcomes (n=9/86), there was
no common drug used in all cases; however, five cases took itraconzole and four cases
took pentamidine (Table 14). Drug commonalities by Acanthamoeba disease
manifestation are also summarized in Table 14. Non-survivors also took many of the
same drugs. Cases that had no information for any drug listed in the database, or that had
unknown outcomes, were taken out of the frequency counts and treated as unknowns.
Among Balamuthia survivors (n=6), there were also no common drugs used in all cases,
although fluconazole and pentamidine was used in all but one instance (Table 15). Drug
commonalities by Balamuthia disease manifestation are also summarized in Table 15.
Again, non-survivors also took many of the same drugs.
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Table 14: Drugs in Common for Non-Keratitis Acanthamoeba Survivors Compared
to Non-Survivors
Drug
No. of Survivors
No. of nonWith Known
Survivors with
Treatment
Known Treatment
All manifestations Itraconazole*
5/9
6/47
Pentamidine
4/9
11/47
Ketoconazole
3/9
6/47
Chlorhexidine topical
3/9
3/47
Amphotericin B
2/9
14/47
Flucytosine
2/9
6/47
Voriconazole
2/9
5/47
Disseminated

Itraconazole
Ketoconazole
Pentamidine
Chlorhexidine topical

GAE
Cutaneous

2/3
2/3
2/3
2/3

4/21
3/21
5/21
1/21

No Survivors
Itraconazole
Pentamidine

2/3
2/3

Rhinosinusitis

No Drugs in
Common for
Survivors (n=2)

Osteomyelitis

1 case

2/7
4/7

Table 15: Drugs in Common for Balamuthia Survivors Compared to Non-Survivors
Drug
No. of Survivors
No. of nonWith Known
Survivors with
Treatment
Known Treatment
All manifestations Fluconazole*
5/6
7/40
Pentamidine*
5/6
6/40
Clarithromycin*
4/6
1/40
Sulfadiazine*
4/6
6/40
Flucytosine*
4/6
4/40
Azithromycin*
3/6
3/40
Ketaconazole
2/6
0/401
Disseminated
GAE

1 case
Azithromycin

2/5

3/35
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Clarithromycin
Fluconazole
Flucytosine
Pentamidine
Sulfadiazine

3/5
4/5
3/5
4/5
3/5

1/35
5/35
4/35
5/35
4/35

See Appendix C for depictions of treatment regimens over time for survivors.
Duration of Illness: Research Question 4
For case-patients who were diagnosed as having Acanthamoeba sp. infection and
who were known to have died (n=77/114), 49% (n=38/77) had missing information on
the number of days between illness onset and death. Of the decedents with known
durations of illness (n=39/77), the mean duration of for illness (onset until death) was
101. The range was from 3 to 765 days. For case-patients with Balamuthia infections
who were known to have died (n=61/70), 39% (n=24/61) had missing information on the
number of days between illness onset and death. Of the decedants with known durations
of illness (n=37/61) the mean duration of illness (onset until death) was 74 days, with a
range of 8 days to 568 days. Based on the data that was seen during the collection and
abstraction work, it appeared that the timing of diagnosis was often quite late in the
course of illness or post-mortem.
Further Data Analysis
Exposures
There was a substantial lack of exposure data for both Acanthamoeba and
Balamuthia cases. Only 6% (n=7/114) of Acanthamoeba cases had information about
water exposured, six had exposures and one did not. Only 4% (n=4/114) had information
about soil exposures; all four cases reportedly had exposure. One case reported an
occupational exposure where the individual worked with animals. Only 20% (n=23/114)
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of Acanthamoeba cases had information about travel and only two out of these included
information about their travel. One case-patient reportedly visited Mexico and one was
noted to have “traveled extensively,” with no further details provided.
Only 17% (n=12/70) Balamuthia cases had information about water exposures;
nine had exposures and three did not. Only 20% (n=14/70) had information about soil
exposure; 12 cases had known exposures whereas two did not. Fifteen (21%) had
occupational exposure information with four reporting actual occupations (three were
farmers/ranchers or living on a farm, one was a firefighter). Half (n=35/70) of the cases
had information about travel history and, of those, 12 gave travel location information
and 23 did not. The country cited most frequently in the travel history was Mexico (7
cases).
Medical History
HIV status was reported for 58% (n=66/114) of Acanthamoeba cases; a minimum
of 52% (n=59/114) of patients who became infected with Acanthamoeba spp. had HIV.
Patients’ AIDS status was known for 53% of cases (n=60/114); a minimum of 47%
(n=54/114) of patients with Acanthamoeba disease had AIDS, of which 81% (n=44/54)
had CD4 counts or another illness that indicated AIDS and 19% (n=10/54) did not.
Past medical history data, when available, also showed a variety of respiratory
illnesses, other immunocompromising conditions, and prescription and illegal drug use,
all of which might have predisposed patients to infection with Acanthamoeba spp. (Table
16). Twelve cases had no information on past medical history.
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Table 16: Past Medical Conditions That May Be Predisposing Factors for NonKeratitis Acanthamoeba spp. Infection (N=102/114)
No. of Cases Reporting Condition
Respiratory Conditions
Pneumonitis
30
Sinusitis
14
Other
5
Deviated Septum
2
TB
2
Nasal Surgery
1
Pharyngitis
1
Immunocompromising Conditions
HIV
Organ transplant
Cancer
Diabetes
Renal failure
Alcohol misuse
Lymphoproliferative disease
Other autoimmune disease
Systemic lupus erthematosus
Other hematologic disease
Cirrohosis

59
22
18
8
7
5
5
4
3
3
1

Treatment/drugs
Steriod use
Immunosuppressants
Eye Infections
Illegal drug use
Excessive antibiotic use
Skin infections

17
16
7
6
1
1

Because HIV/AIDS seemed to be so frequent among the Acanthamoeba cases, a further
breakdown of other immunocompromising illnesses was done by HIV status. See Table
17.
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Table 17: Positive Non-Keratitis Acanthamoeba Patients Reporting Another
Immunocompromising Condition by HIV Status
Immunocompromising
No. of HIV-Positive No. of HIVNo. of HIV
Conditions
Cases Reporting
Negative
Unknown
Another Condition
Cases
Cases
(n=7/59)*
Reporting
Reporting
Another
Another
Condition
Condition
(n=7/7)**
(n=27/48)***
Cancer
3
2
13
Alcohol Misuse
2
2
1
Other Hematologic Disease
2
0
1
Renal failure
1
1
5
Other Autoimmune Disease
1
1
2
Organ Transplant
0
5
17
Diabetes
0
2
6
Systemic Lupus
0
1
2
Erythematosus
Lymphoproliferative Disease
0
0
4
Cirrhosis
0
0
1
*Two HIV-positive Acanthamoeba cases had multiple immunocompromising conditions.
**Five HIV-negative cases had multiple immunocompromising conditions.
*** Eighteen cases had multiple immunocompromising conditions.
Other hematologic disease included: end-stage renal disease, hemophilia, and
myelodysplastic syndrome.
Other autoimmune disease included: progressive transverse myelitis, graft vs. host
disease, hemolytic anemia, and discoid lupis; hypogammaglobullnemia.

Unlike Acanthamoeba spp. infection, Balamuthia cases did not typically have
HIV. Fifty-six percent of cases had an unknown HIV status (n=39/70). Of the 31 cases
with a known status, only 26% (n=8/31) were HIV positive and 74% (n=23/31) were
negative. Of the eight cases that had HIV, four had progressed to AIDS. See Table 18
for previous medical history that may predispose patients to infection with Balamuthia
mandrillaris. Twenty-four cases had no information on past medical conditions.
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Table 18: Past Medical Conditions That May Be Predisposing Factors for
Balamuthia mandrillas Infection (N=46/70)
No. of Cases Reporting Condition
Respiratory Conditions
Otitis
6
Pharyngitis
3
Pneumonitis
3
TB
3
Other
2
Deviated Septum
1
Nasal surgery
1
Sinusitis
1
Immunocompromising Conditions
Alcohol misuse
HIV
Diabetes
Organ transplant
Renal failure
Other hematologic disease
Cirrohosis
Treatment/drugs
Illegal drug use
Skin infections
Steriod use
Initial and Final Diagnoses and Outcomes

9
8
4
3
3
2
1

14
3
3

Seventy-eight percent of Acanthamoeba cases had missing data for admitting
diagnosis (n=89/114). Rarely, 8% of the time, were cases diagnosed with meningitis
(n=1/25) or meningoencephalitis (1/25): such cases were typically diagnosed as other
illness (92%, n=23/25) such as toxoplasmosis (n=3/23), toxoplasmosis vs. or with
lymphoma (n=3/23), or vasculitis (n=3/23). The remaining initial diagnoses (n=14/23)
were varied. Final diagnosis of Acanthamoeba cases are shown below in Table 19.
Table 19: Final Diagnosis of Cases of Non-Keratitis Acanthamoeba spp. Infection
No. of Cases
Percent
Acanthamoeba GAE
48
42%
Disseminated acanthamoebiasis
36
32%
Acanthamoeba rhinosinusitis
6
5%
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Cutaneous acanthamoebiasis
Other: Acanthamoeba
osteomyelitis
Total

23
1

20%
1%

114

100%

Forty percent of Balamuthia cases had missing data for admitting diagnosis (n=28/70).
As with Acanthamoeba infection, Balamuthia cases were rarely (26%, n=12/42)
diagnosed with encephalitis (n=3/12), meningitis (n=6/12), or meningoencephalitis
(n=3/12) on initial presentation, and more commonly diagnosed with other illnesses
(74%, n=30/42) such as cysticercosis/neurocysticercosis (n=3/30), toxoplasmosis
(n=3/30), stroke (n=2/30), neoplasia (n=3/30), or acute disseminated encephalomyelitis
(ADEM) (n=2/30). The remaining initial diagnoses (n=25/30) were varied. Final
diagnosis of Balamuthia cases are shown below in Table 20.
Table 20: Final Diagnosis of Cases of Balamuthia mandrillaris Infection
No. of Cases
Percent
Balamuthia GAE
62
89%
Disseminated balamuthiasis
8
11%
Total
70
100%
Outcomes for both Acanthamoeba and Balamuthia infections were poor. Twentyeight cases of Acanthamoeba had unknown outcomes (25%, n=114). Of the cases with
known outcomes, 10% of case-patients survived (n=9/86) and 90% died (n=77/86).
Prognosis for those with Balamuthia infection was similar. Three cases had unknown
outcomes (4%, n=70). Of the cases with known outcomes, 9% survived (n=6/67)
survived and 91% died (n=61/67).

CHAPTER V: DISCUSSION AND CONCLUSION
In examining the demographics of both Acanthamoeba and Balamuthia cases, the
fact that the disease manifestations are far more common in men than women was one of
the only conclusions that could be drawn from the data. The completeness of answers for
this question was almost 100% in both Acanthamoeba and Balamuthia datasets.
Similarly, the data on age was more than 96% complete for both groups. The vast
majority (87%) of Acanthamoeba cases occurred in adults aged 18–64 years with a mean
age of 38.8 years. However, the pattern for Balamuthia cases tended towards younger
persons; while most (47%) were still adults 18–64 years of age, a large proportion of
Balamuthia cases (43%) occurred in children younger than 18 years of age.
The scarcity of ethnicity data makes it difficult to interpret an epidemiologic
pattern of this variable. More than 90% of the ethnicity data for Acanthamoeba cases
was missing. While 82% (n=9/11) of patients with known ethnicity were Hispanic, a
denominator of 11 is insufficient to draw conclusions. For Balamuthia cases, 59% of the
ethnicity data was unknown. As with Acanthamoeba case-patients, while Hispanics did
make up the majority, 76% (n=22/29), when the ethnicity of the Balamuthia case-patients
was known, a denominator of 29 may not be enough to draw conclusions from. Schuster,
Glaser, Honarmand, Maguire, and Visvesvara (2004) proposed that Hispanics may be at
increased risk for Balamuthia mandrillaris infection based on the results of seven
positive tests, all in Hispanic patients, conducted by the California Encephalitis Project
(CEP) and because 8 of 11 cases in the State occurred in Hispanic Americans.20 The
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authors also searched CDC records and state that “approximately 50% of the 50 North
American patients” were Hispanic; this number is potentially biased as it is based on the
assumption that certain surnames were ethnically Hispanic. Also, because the California
State Health Department has the CEP, data from that state may over-represent Hispanics
because there are a high number of persons of that ethnicity in the state (37% based on
U.S. Census estimates in 2009).29
However, some suggestion of an ethnicity bias is present in the Balamuthia data.
This thesis also examined case records at CDC and in the published literature. In looking
at the national proportion of Hispanic ethnicity in 1999, the median year of the
Balamuthia dataset, it was11.5%.30 Even though the ethnicity was unknown for 41
Balamuthia case-patients, 22 (31%) of the total Balamuthia cases (n=70) were of known
Hispanic ethnicity, which is already greater than the population proportion. And while
the suggestion that balamuthiasis might be more common in Hispanics versus nonHispanics may be true, the cause of this possible association is unknown and might
reflect a number of factors, possibly including different exposure patterns.
In looking at the geographic distribution of cases, there is no apparent pattern by
state of treatment, with cases being treated in all regions of the continental United States.
For both Acathamoeba and Balamuthia, those states reporting more cases tended to be
the states with larger State health departments. Although exposure patterns might be
different in some states, it’s worth considering that the large number of cases reported in
California might be due to its ongoing CEP. Similarly the large number of cases from
Texas might be because of its proximity to and awareness of the CEP’s work. Because
the CEP conducts active surveillance on cases of encephalitis, it may be that the numbers
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of free-living ameba cases from California and Texas indicate that cases are more
frequent than supposed and are being diagnosed because the cause of encephalitis is
being closely looked at.
Presenting symptom information is not encouraging in terms of gaining a better
understanding of how to more rapidly suspect and thereby diagnosis and treat free-living
amebae infection. Much of the presenting symptom information was missing from cases
diagnosed with Acanthamoeba GAE, ranging from 48% missing on general symptoms to
90% missing visual symptoms. Gaps in visual symptom and neurologic symptom data
were also apparent for disseminated acanthamoebiasis cases and in each symptom
category for cutaneous cases, with the exception of presenting skin lesions. Even among
the cutaneous cases, the type of lesion seen on presentation was highly variable and not
pathognomonic. While both Acanthamoeba GAE and disseminated acanthamoebiasis
had fever and headache as the predominant general symptoms and other neurologic
deficits and weakness were typical neurologic symptoms, these symptoms and signs are
rather vague symptoms and can indicate many types of illness. It may be that there are
specific neurologic deficits that could stand out if the data were more complete.
In contrast, cases diagnosed with Balamuthia GAE or disseminated balamuthiasis
had better completion of data for both presenting general symptoms (34% missing) and
neurologic symptoms (23% missing). Similar to Acanthamoeba, headache was common
among GAE and disseminated cases, but vomiting also was high on the list of common
symptoms, with fever more evident in GAE cases than in disseminated cases.
Interestingly, unlike Acanthamoeba, infection with Balamuthia was not noted to have any
symptoms related to sinus problems, nor were there documented cases of Balamuthia
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rhinosinuitis. Also there were no standalone cases of cutaneous balamuthiasis, and skin
manifestations only occurred in cases of disseminated infections. All disseminated cases
had granulomatous amebic encephalitis and a second disease manifestation (most often
skin), whereas disseminated infections of acanthamoebiasis were more varied in their
manifestations with only 11 of the 30 cases having proven GAE.
The generality of signs and symptoms for both Acanthamoeba and Balamuthia
are reflected in the initial diagnoses. Although the data were limited, the classical
diagnoses for headaches and fevers (i.e., meningitis, encephalitis, and
meningoencephalitis) were not commonly made. Rather, other diagnoses were more
common, including: parasitic diseases (e.g., toxoplasmosis, cysticercosis,
neurocysticercosis), neoplasias, vasculitis, or stroke. The variables other neurologic
symptoms, other general symptoms, and other visual symptoms should be more closely
examined to determine if there any signs or symptoms for these variables that suggest a
unique symptom for free-living ameba infection.
Examination of the treatment regimens in survivors of acanthamoebiasis shows
that while there were several common drugs administered to the survivors, the same
drugs were used in non-survivors. A closer examination of the combination of drugs
used needs to be done to determine if there is a combined therapy that is more effective.
Balamuthiasis differs in that the two manifestations of the disease reported have always
involved the central nervous system. As with acanthamoebiasis, drugs in common usage
for the survivors were often used in non-survivors. Again, closer examination of the
combination of drugs used needs to be done. Duration and dosage are also important
factors, but unfortunately much of the dosage information or dosage timing is missing
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from this retrospective review. So going forward in data collection for an informal
surveillance system of free-living amebas, it is essential that accurate treatment
information is collected for closer examination of whether or not certain drugs are more
effective than others.
The mean number of days from illness onset to death for cases of Balamuthia
mandrillaris was 74 and for Acanthamoeba spp. was 100 days. This seems to indicate
that there is sufficient time to make a correct diagnosis, but further evaluation of the data
is necessary to examine the timing of hospitalization, timing of a correct diagnosis, and
timing of treatment specific to free-living ameba infection. If it is determined that
sufficient time exists for a correct diagnosis, then the question becomes how to increase
awareness of these infections so they are included in a differential diagnosis when
patients present with symptoms that tend to be very common to various forms of
meningitis, and where other potential diagnoses such as toxoplasmosis,
neurocysticercosis, and tumors are often considered far more quickly.
Outside of the main research questions, much of the other data explored was
inconclusive. The epidemic curve for Acanthamoeba spp. infection shows the highest
number of cases between 1994 and 1997 with an apparent drop off in reported cases after
2003. Because the infection is rare, this is difficult to interpret. The increase of cases in
the 1990s is likely due to greater awareness of the infection and increased requests to the
Centers for Disease Control and Prevention for diagnostic assistance. Are the cases
really decreasing, or are other laboratories beginning to perform diagnostic testing and
therefore CDC is not receiving specimens or reports? It is important to continue to
monitor cases to see if there truly is this drop in cases or if the number of infections
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remains relatively constant over time. Because Balamuthia was not recognized as the
cause of human infections until around 1990, the epidemic curve is not particularly
surprising, with some fluctuations throughout the 1990s and then a seeming increase in
cases in more recent years, again likely due to greater awareness of free-living ameba
infections.
The exposure data were too scarce to draw conclusions from in terms of modes of
transmission (i.e., water, soil). While persons with Naegleria fowleri often have a history
of swimming and recreational water activities in freshwater, persons with Acanthamoeba,
where exposure history was known, had both water and soil exposures, as did those with
Balamuthia. The types of water bodies, water conditions, and recreational water
activities are data that are not known in these cases.
The data did strongly support the supposition that Acanthamoeba infection
disproportionately affect immunocompromised persons. Outside of those with HIV, it
appears that steroids and immunosuppressant drugs may be important conditions.
Although not necessarily associated with immunosuppression, a history of pneumonitis
also seemed to be common. This might reflect a compromised portal of entry for the
pathogens or perhaps pneumonitis is a common co-morbidity in those Acanthmaoeba
patients with AIDS. The past medical history for Balamuthia mandrillaris cases is less
revealing, although drug and alcohol abuse appeared to be a relatively common
potentially immunosuppressive condition as well as a variety of respiratory conditions.
The data exploration for this thesis was limited and the data collected for CDC’s
informal surveillance system for free-living amebas has more information to be accessed
and analyzed. It will be important, as noted above, to look closer at the timing of onset,
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hospitalization, diagnosis, and death or survival in hope that there may be some
information that might be useful in improving clinical outcomes. Because so little data
on U.S. cases is available, fewer than 200 cases with much missing data, it is crucial to
gather as much information as possible about exposure, presentation, and treatment of
future cases. This exploration has been the first comprehensive look at all known cases
of Acanthamoeba and Balamuthia infection in 20 years and it contributes to a broader
understanding of these illnesses.
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Appendix A: Detailed Tables of All Published Non-Keratitis Acanthamoeba and
Balamuthia Cases
Table 1: Disseminated Acanthamoebiasis
Case
(Ref)

Yr

State

Age
(yr)

121,27,3

1972

TX

7

M

Black/
Unknown

26,17,21,

1977

CA

24

F

Unknown/
Hispanic

36,35

1978

UT

57

F

Unknown/
Unknown

46,36

1980

PA

38

M

White/
Unknown

522,24,3

1983

FL

29

M

66,22,23,

1985

CA

34

M

Unknown/
Unknown
(Haitian)
Uknown/
Unknown
(Mexican
American)

76,40,42

1987

CA

35

M

86,24,43

1989

OH

34

96,22,23,

1989

IL

1039,45

1990

1122,24,

1990

1-33

27,34

7-40

39,41

44

39,40,46

Sex

Race
/Ethnicity

Health
Status
Pharyngitis,
water & soil
exposure
Unknown

Type of
Illness
GAE,
keratitis

Clinical
Course in
Days*
~44 (s);
7 (h)

Died
Y

GAE, skin,
sinus, lymph
node,
adrenals,
thyroid
GAE, lungs,
skin

~229 (s);
~49 (h)

Y

~8 (s);
~3 (h)

Y

~43 (h);
[Possibly
720 days
(s)]
~138 (s);
108 (h)

Y

AIDS

GAE, skin,
pulmonary
hyaline
membrane
sinus, skin

AIDS

GAE, skin

Black/
Unknown

AIDS, PCP,
IVDA

M

Unknown/
Unknown

38

M

GAE, skin

~24 (h)

Y

MA

39

M

AIDS

GAE, lungs

7

M

HIV,
demyelinating polyneuropathy

skin, sinus

~8 (s);
4 (h)
~193 (s)

Y

PA

White/
Unknown
Unknown/
Unknown
Unknown/
Hispanic

AIDS,
recurrent
otitis
AIDS, PCP

skin,
keratitis,
lungs
skin, sinus

~9 (s);
~2 (h);
[Possibly
374 days
(s)]
~92 after
diagnosis;
8 (h)
~210 (s)

66

Systemic
lupus
erthematosu
s
Kidney
transplant

Y
Y

Y
Y

Y

67
1247

1991

TX

39

F

Unknown/
Unknown

1322,24,

1991

OR

33

M

Unknown/
Unknown

1422,40,

1992

CA

47

M

Unknown/
Hispanic

1522,40,

1992

CA

36

M

1640,49

1993

TX

.8

M

American
Indian/
Unknown
Black/
Unknown

1722,50

1994

Unkn
own

5

M

Black/
Unknown

HIV, PCP

1822,40,

1994

CA

45

M

White/
Unknown

1922,40,

1994

CA

34

M

White/
Unknown

47

2022,34,

1994
?

TX

32

F

Unknown/
Unknown

2151

1995

NY

33

M

Black/
Unknown

2224,40

1995

MA

37

M

Unknown/
Unknown

AIDS, PCP,
chronic
sinusitis
AIDS, PCP,
chronic
sinusitis
AML, bone
marrow
transplant,
sinusitis
AIDS, HIVrelated
cerebral
atrophy
AIDS

2334,52

1997

SC

39

F

2453

2000

Unkn
own

37

M

Black/
Unknown
Unknown/
Unknown

39,40,48

42

42

42

42

CML, bone
marrow
transplant,
pneumonia
AIDS, PCP,
sinusitis

GAE, lungs,
adrenalitis

~25 (s)

Y

skin, sinus

Y

AIDS, PCP,
HIV wasting
sickness
AIDS, PCP

skin, sinus

~123 (s)
until
lesions
resolved,
treatment
con’t for 8
mo. after
~120 (h)

Y

skin, sinus

~120 (h)

Y

skin, lungs,
lymph node,
heart,
kidney,
spleen
skin, osteomyelitis

~765 (s)

Y

~810 (s),
with
occasional
skin
lesions
recurring
~120 (h)

N

Y

GAE, skin,
sinus

~111 (s)

Y

GAE, skin

~18 (s)

Y

skin, sinus

~42 (s); tx
for another
150 days
until death
Min ~90 (s)

Y

HIV

Lung
transplant
AIDS, nonHodgkins
lymphoma

skin, sinus,
bone

skin, sinus
skin, liver,
BAL
skin, sinus

~124 (s);
118 (h)
~131, tx
continued
after with
no
evidence
of
recurrent
infection

Unk
now
n
N
N

68
2540,54

2000

Unkn
own

42

M

Unknown/
Unknown

2655

2001

GA

45

M

Unknown/
Unknown

2734

2001

MD

61

F

Unknown/
Unknown

2822,40,

2001

FL

35

F

2957,58

2003

TX

60

M

Unknown/
Unknown
(Nicaragua
n)
White/Unk
nown

56

AIDS,
peripheral
neuropathy
Acute
myelogenous
leukemia,
stem cell
transplant
Kidney
transplant,
renal failure
AIDS,
recurrent
sinus surgery

sinus, lungs

~19 (s); 16
(h)

Y

GAE, lung

~98 (s);
3 (h)

Y

skin, bone

~26+ (h)

Y

skin, sinus

Unknown

Y

Bilateral lung GAE, skin,
~38 (s); 17
transplant;
lung
(h)
water
exposure
*Clinical course may mean from symptom onset until death or resolution of illness (s) or from
presentation/hospitalization until death or resolution of illness (h).
AIDS = Acquired Immune Deficiency Syndrome; HIV = Human Immunodeficiency Virus; PCP =
Pneumocystis carinii pneumonia, IVDA = intravenous drug abuse; CML = chronic myelogenous
leukemia; AML = acute myeloid leukemia

Y

Table 2: Disseminated Balamuthiasis
Case
(Ref)

Yr

State

Age
(yr)

Sex

Race/
Ethnicity

16,17,59

1975

LA

56

M

Black/
Unknown

26,16,23,

1985

NY

36

M

Unknown/
Unknown

316,23

1989

GA

52

M

462

1996

CA

64

M

Unknown/
Unknown
White/
Unknown

563

1999

CA

2

F

664

1999

TX

38

M

765

1999

TX

89

M

60,61

Unknown/
Hispanic
Unknown/
Hispanic
Unknown/
Unknown

Health
Status

Type of
Illness

Alcohol
misuse,
G6PD
HIV, IVDA

GAE,
pancreas

Amputation,
soil exposure
Ankylosing
spondylitis,
gardening
Otitis media
IVDA

Clinical
Course
in Days
~27 (s);
13 (h)

Died
Y

GAE,
kidney,
adrenals
GAE,
cutaneous
GAE,
cutaneous

~25 (s);
~18 (h)

Y

~101 (s);
~77 (h)
Unknown

Y

GAE, lungs

~24 (s); 9
(h)
~568 (s);
19 (h)
~390 (s);
13 (h)

GAE,
cutaneous
CSF,
cutaneous

Coronary
artery
disease, mild
congestive
heart failure
*Clinical course may mean from symptom onset until death or resolution of illness (s) or from
presentation/hospitalization until death or resolution of illness (h).

N
Y
Y
Y

69
HIV = Human Immunodeficiency Virus ; G6PD = glucose-6-phospate dehydrogenase deficiency;
IVDA = intravenous drug abuse

Table 3: Acanthamoeba GAE
Case
(Ref)

Yr

State

Age
(yr)

Sex

Race/
Ethnicity

16,17,21,26,

1955

AZ

6

F

266

1964

TX

59

M

36,17,27,67

1971

PA

58

M

Unknown/
Unknown
Unknown/
Unknown
Unknown/
Unknown

46,27,68

1971

NY

57

M

Unknown/
Unknown

56,14,15,17,

1972

NY?

27

M

White/
Unknown

66,17,21

1976

LA

32

F

76

1978

NY

11

F

86

1978

TX

2

F

96,22,23

1981

GA

31

F

106,23,39,6

1985

CA

34

M

116,23,39

1987

GA

34

M

126

1988

MN

60

M

136

1988

SC

38

M

1423,39

1990

GA

34

M

1570

NM

35

M

1671

1997
?
1997

CT

47

F

White/
Unknown
Unknown/
Unknown
Unknown/
Unknown
Unknown/
Unknown
Unknown/
Unknown
Unknown/
Uknown
Unknown/
Unknown
Unknown/
Unknown
Unknown/
Unknown
Unknown/
Unknown
Unknown/
Unknown

1772

2003

PA

40

M

Unknown/
Unknown

1873,74

2003

TN

70

F

White/
Unknown

27

27

9

Health Status

Clinical
Course in
Days
~252 (s);
16 (h)
21 (h)

Y

~21 (h)

Y

Unknown

Y

31 (s);
5 (h)

Y

~43 (s)

Y

Unknown, soil
exposure
Unknown

Unknown

Y

Unknown

Unknown

Mixed connective
tissue disorder
HIV, PCP

Y

AIDS, PCP

~40 (s);
9 (h)
~35 (s);
~28 (h)
8 (s); 4 (h)

Unknown

Unknown

Unknown

Unknown

Unknown

Unknown

AIDS, PCP

~15 (s); 8 (h)

Y

IVDA, alcohol
abuse
Moncytoid B cell
lymphoma, stem
cell transplant

~11 (s)

Y

~143 (s);
11 (h)

Y

~14 (s);
12 (h)

Y

~99 (s);
63 (h)

Y

Unknown
Drug abuse,
cirrhosis
Alcohol abuse,
pneumonia, water
exposure
History of stroke,
intestinal
amebiasis, water
exposure
Hodgkins, longterm immunesuppression, mild
respiratory
infections
Pneumonitis

Multiple visceral
transplant,
immunesuppressants
Discoid lupus
erthematosus

Died
Y

Y
s

70
1975

2004

Unkn
won

51

M

White/
Unknown

2076

2005

VA

41

M

2177

2006
?

MA

24

F

Black/
Unknown
Unknown/
Unknown

Kidney transplant,
diabetes, potential
water exposure
HIV

~54 (s)

Y

~9 (s)

Y

Systemic lupus
~120 (s);
Y
erythematosus,
60 (h)
drug and alcohol
dependency
*Clinical course may mean from symptom onset until death or resolution of illness (s) or from
presentation/hospitalization until death or resolution of illness (h).
AIDS = Acquired Immune Deficiency Syndrome; HIV = Human Immunodeficiency Virus; PCP =
Pneumocystis carinii pneumonia, IVDA = intravenous drug abuse

Table 4: Balamuthia GAE
Case
(Ref)
16,17,27,

VA

Age
(yr)
47

1974

F

26,16,78,

1978

SC

.4

M

36,16,79,

1979

PA

2.5

M

46,16,79

1982

CA

.8

F

56,16

1983

FL

61

M

66

1984

CA

72

M

76,16,79,

1986

TX

11

F

816

1990

NV

60

M

982

1990

NC

1.5

M

1083

1991

TX

.11

F

1184

1991

NV

.6

F

1279

1992

AZ

13

F

1385

1993

TX

5

M

1479

1993

AZ

2.3

M

1585

1993

TX

15

M

1686

1995

MD

34

F

1787,88

1996

CA

32

M

28

79

80

81

Yr

State

Sex

Race/
Ethnicity
Black/
Unknown
White/
Unknown
Unknown/
Unknown
Unknown/
Unknown
Unknown/
Unknown
Unknown/
Unknown
Unknown/
Hispanic
Unknown/
Unknown
Unknown/
Unknown
Unknown/
Hispanic
Unknown/
Unknown
Unknown/
Unknown
White/
Unknown
Unknown/
Unknown
Unknown/
Hispanic
Unknown/
Unknown
Unknown/

Health
Status
Diabetes,
well water
Seizure
activity,
pneumonia
Unknown

Clinical Course
in Days
~21 (s); 7 (h)

Y

~35 (s); 5 (h)

Y

240 (s)

Y

Unknown

15 (s)

Y

Alcohol
misuse, TB
Unknown

112 (s)

Y

Unknown

Y

150 (s)

Y

Unknown

Y

~23 (h)

Y

~28 (s)

Y

Healthy, soil
exposure
Alcohol
misuse
Unknown,
water
exposure
Healthy

Died

Otitis,
pharyngitis
Healthy

~25 (h)

Y

~16 (s)

Y

Healthy

~57 (s)

Y

Otitis

~23 (s)

Y

Healthy

~72 (s)

Y

HIV

~24 (h)

Y

IVDA,

~42 (s)

Y

71
Hispanic
1889

1996

CO

3

M

1990

1999

MA

52

F

2091

1999

VT

5

F

Unknown/
Unknown

2162,88

2000

CA

5

F

227,8,63

2001

CA

3

F

2363

2001

TX

2

M

2463,93,

2001

CA

7

M

2593

2002

CA

64

M

Unknown/
Hispanic
White/
Hispanic
Unknown/
Hispanic
Unknown/
Hispanic
Unknown/
Hispanic

2695

2002

FL

40

M

2796

2002

NY

72

F

2893,94

2003

CA

7

M

2993

2005

CA

19

M

3093

2005

CA

12

M

3193

2007

CA

35

M

3297

2007

KY

2

M

3393,98

2007

CA

43

M

3499

2007

Unkno
wn

Unk
now
n

Unk
now
n

Unknown/
Unknown

3593

2007

CA

72

M

Pacific
Islander/
Unknown

,92,93

94

Unknown/
Unknown
Unknown/
Unknown

Unknown/
Unknown
Unknown/
Unknown
Unknown/
Hispanic
Unknown/
Hispanic
Unknown/
Hispanic
Unknown/
Hispanic
Unknown/
Unknown
White/
Unknown

alcohol
misuse
Pharyngitis

~17 (s)

Y

~105 (s)

Y

75 (h)

Y
N

Otitis

~485 (h); multiple
hospitalizations
~24 (s)

Y

Unknown

Unknown

Y

Unknown

~45 (s)

Y

Unknown,
occupational
soil
exposure
Alcohol and
drug abuse
Healthy, soil
exposure
Steroid
therapy
Former drug
abuse
Unknown,
soil
exposure
Unknown

~8 (s)

Y

~10 (h)

Y

~27 (s)

N

3 (h) from final
hospitalization
8 (h)

Y
Y

120 (h)

Y

Unknown

N

Healthy

~62 (h)

N

Pneumonia,
idiopathic
thrombocytopenic
purpura,
occupational
soil
exposure
Multiple
visceral
organ
transplant
Unknown,
gardening

~117 (s)

Y

Unknown

Y

7 (h)

Y

Chronic
sinus
infections,
chronic
idiopathic
neutropenia
Healthy,
water
exposure
Healthy

72
3693

2008

CA

1.6

M

3718

2009

MS

4

M

Unknown/
Hispanic
Unknown/
Unknown

Unknown

35 (h)

Y

Influenza A, ~12 (s)
water & soil
exposure
3818
2009
MS
31
F
Unknown/
Kidney
~55 d (s)
Unknown
transplant
3918
2009
MS
27
M
Unknown/
Kidney
~139 (s)
Unknown
transplant
*Clinical course may mean from symptom onset until death or resolution of illness (s) or from
presentation/hospitalization until death or resolution of illness (h).
TB = Tuberculosis; HIV = Human Immunodeficiency Virus; IVDA = intravenous drug abuse

Y
Y
N

Table 5: Cutaneous acanthamoebiasis
Case
(Ref)
16,22,39,1

NY

Age
(yr)
38

1989

M

222,23,39,

1990

IL

60

M

322,39,40

1991

CA

30

M

439,101

1991

VA

42

M

522,34,102

1992

NY

31

M

622,103

1994

DC

44

M

Unknown/
Unknown

722,40,104

1995
?

CA

38

M

White/
Unknown

822,105

1996

CA

27

F

922,106

MI

44

M

MI

38

M

11107

1997
?
1997
?
2003

MD

51

F

12108

2004

CA

52

F

Unknown /
Hispanic
Unknown/
Unknown
Unknown/
Unknown
Unknown/
Unknown
Unknown/
Unknown

00

44

1022,106

Yr

State

Sex

Race/
Ethnicity
Unknown/
Unknown
Unknown/
Hispanic
Unknown/
Unknown
Unknown/
Unknown
Unknown/
Unknown

Health Status

Clinical Course
in Days
>21 (s)

Y

~40 (s)

Y

AIDS, PCP,
chronic
sinusitis
AIDS

~77 (s)

Y

42 (s)

Y

ESRD, Kidney
transplant,
diabetes
AIDS,
progressive
myelitis,
peripheral
neuropathy,
water exposure
AIDS, PCP,
chronic
sinusitis, water
exposure
AIDS

~420 (s), con’t
treatment after
lesions resolved
~450 (s)

N
Y

Unknown

Y

~240 (s)

Y

AIDS, TB

~180 (s)

Y

AIDS

~62 (s)

Y

AIDS, PCP

~31 (s)

N

Lung
transplant,
immuneSuppressants,
creek as
drinking water
source

~150 (h)

N

HIV,
pneumonia
AIDS, PCP

Died

73
*Clinical course may mean from symptom onset until death or resolution of illness(s) or from
presentation/hospitalization until death or resolution of illness (h).
AIDS = Acquired Immune Deficiency Syndrome; HIV = Human Immunodeficiency Virus; PCP =
Pneumocystis carinii pneumonia, ESRD = end-stage renal disease; TB = Tuberculosis

Table 6: Acanthamoeba Rhinosinusitis
Case
(Ref)

Yr

State

Age
(yr)

Sex

Race/
Ethnicity

Health Status

Unknown/
Unknown
Unknown/
Unknown

HIV, chronic sinusitis

153

1994

Unk

45

M

2109

2005

FL

49

F

Clinical
Course in
Days
Unknown

Bilateral lung
Unknown
transplant, immunosuppressants,
steroids
*Clinical course may mean from symptom onset until death or resolution of illness (s) or from
presentation/hospitalization until death or resolution of illness (h).
HIV = Human Immunodeficiency Virus

Died
N
N

Table 7: Acanthamoeba osteomyelitis
Case
(Ref)
1110

Yr

State

Age
(yr)
32

Sex

Race/
Health
Clinical Course in
Died
\Ethnicity
Status
Days
1979
PA
F
White/
Suspected
Unknown
N
Unknown
diabetes
*Clinical course may mean from symptom onset until death or resolution of illness (s) or from
presentation/hospitalization until death or resolution of illness (h).
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Date of Report:
Demographics
Patient’s Last Name

First

M.I.

Age

Gender:
Male

Unknown

Race:

Ethnicity:
Hispanic

Unknown

Non-Hispanic
Immigrant?

Female

Yes

No

□

White

Asian/Pacific Islander

Unknown

County and State of Residence: _

_________________

Black

American Indian

Other __

County and State of Treatment: __

________________

Unknown

Country of origin: _____

Occupation: ____

___

_________

Length of time since immigrated: _____________

Exposure History
County/State of Suspected Exposure:

/

Source of possible exposure, if known:
Water
Exposures
Yes
No
Unknown

(please check all that apply and provide best estimates of dates)

Date(s):
Type:
Date(s):
Type:
__
__
__
__
Canal
Private Club Pool
__
__
__
__
Lake
Private Home Pool
__
__
__
__
Pond
Fill-and-Drain Pool
__
__
__
__
Ocean
Hotel Pool
__
__
__
__
River/Stream
Spring (hot/cold)
__
__
__
Well
Spa/hot tub/whirlpool __
Other, specify ___________________________
Date(s):

If “yes”, please
fill out section on
right

Yes
Water Activities
Yes
No
Unknown
If “yes”, please
fill out specifics
on right
Soil Exposures
Yes
No
Unknown
If “yes”, please
fill out specifics
on right

Number of persons exposed (if known):

No

Unknown

Diving into water
Inhaled water
Jumped into water
Swallowed water

Yes

No

Date(s):
__
__
__
__
__
__
__
__

Unknown

Snorkeling/scuba diving
Swimming
Water sports (skiing etc.)
Wore nose clip or plugged
nose when jumping/diving
Other, specify

Splashed water

Route of Entry if
known:
(please check all that
apply)

Type:
Community Pool
Apartment Pool
Fountain
Water park

Type:
Date(s):
__
__
Gardening
__
__
Composting
__
__
Farm/Ranch
Other, specify: _____
Date(s):

Inhalation
Ingestion

Contact
Via Wound

Occupational
Exposures
Yes
No
Unknown
__
If “yes”, please
fill out specifics
on right

Farmer/rancher
Firefighter
Lifeguard/pool attendant
Other, specify: _________

Other, specify:

If Water Source , Please List Source Characteristics:
Name of Water Exposure:
Size of Body Water: □ < 10 acres
□ 10-100 acres □ >100 acres
□ Unknown
F/C
Ambient Air Temperature:

Geospatial Coordinates:
□ Water level: □ Low □ High
Water Turbidity: □ Clear
Cloudy □ Murky □ Unknown
□ Normal □ Flood Stage
□ Unknown
Depth: __
__
Water Temperature: ___F/C

Thermally Polluted: Y / N
Flow Rate: □ Slow
□ Normal □ Fast
□ Unknown
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Yes

Travel History last 2 years:

No

Unknown

If yes, please specify in table below:

Locations

Dates (from – to)

Past Medical History:

Please check all conditions/symptoms that patient has currently or has had within past 2 years:
Treatment/drugs:

HIV/AIDS:

Excessive antibiotic use (specify in Provider
comments)
_________

Illegal drug use, specify:__
Immunosuppressants
Radiation therapy

HIV
AIDS

Yes

No

Unknown

Yes

No

Unknown

On
Antiretrovirals

Yes

No

Unknown

Steroid use
Other Immunocompromised Conditions
Alcohol misuse
Diabetes mellitus
G6PD deficiency
Liver cirrhosis
Malnourishment
Pregnancy (recent)
Renal failure
Lymphoproliferative disease
Systemic Lupus Erythematosus (SLE)
Cancer,
specify:______________________________
Other hematologic disease, specify:
______________
Other autoimmune disease, specify:
______________
Organ transplant, specify:
______________________
ENT/Respiratory:
Otitis
Rhinitis
Broken Nose
Deviated septum
Tuberculosis
Other lung disease, specify:

Sinusitis
Epistaxis
Nasal Surgery
Pharyngitis
Pneumonitis

Other Conditions:
Dermatitis
Skin infections
Eye infection
Other, specify: ________________________
Injury, specify: ________________________

Current Illness
Date of Illness onset:

Duration of illness: (in days)

Was patient admitted to hospital for current illness?
If Yes, Date of most recent hospitalization:

Yes

Hospital Name:___

City:___

No
Unknown
Duration of most recent hospitalization (in days):
_____________

State:

__

Physician Name 1:___

_____________

E-mail (if avail): ___

__________

Phone: ___

____

Physician Name 2:___

_____________

E-mail (if avail): ___

__________

Phone: ___

____

Other Recent Hospitalizations:

Yes

Dates (from- to)

No

Unknown
Diagnosis
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History of Present Illness:
Please provide a brief description of the patient’s clinical course, prior to hospitalization:

Signs/Symptoms on Presentation (most recent hospitalization):
Vital
Signs:_________________________________________________________________________________________
_
Temperature: _
_
___mmHg

_F/C

P: _

_ bpm

R= __

General:_____________________________________
______
Duration
Duration
(days)
(days)
Fever
Myalgia
Nausea
Back Pain
Vomiting
Cough
Diarrhea
Shortness of breath
Weight loss
Sinus problems
Anorexia
Abnormal reflexes
Headache
Disorientation
Stiff neck
Lethargy/fatigue
Other general symptom/sign,
specify:_
________

_breaths/min

BP:

Visual______________________
Duration
(days)
Blurred vision
Diplopia
Photophobia
Other visual changes, specify:
_________

Neurologic:_______________________________________________________________________________________
Duration
(days)

Duration
(days)

Altered mental status
Aphasia
Ataxia
Behavioral changes
Coma
Confusion
Cranial nerve VI deficit
Cranial nerve VII deficit

Dysphagia

Yes

Lesion type

Weakness
Hemiparesis/Hemiplegia
Altered sense of taste
Altered sense of smell
Decerebrate posturing
Decorticate posturing
Fixed, nonreactive pupils
Dilated pupils

Facial numbness/Parathesia

Hallucinations
Combativeness
Hyperreflexia
Loss of balance
Numbness
Seizures

Cranial nerve XII deficit
Other cranial nerve deficit,
specify:
______
___
Skin Lesions:

Duration
(days)

No

Upgoing toes
Duration:

Unknown

Nystagmus
Other neurologic deficit,
specify:

Duration:

If yes, please specify in table below:

Anatomic location

Ulcers
Plaques
Erythematous nodules
Other
Other Symptoms/Signs:
Other, specify:_
______________________

Size

Number

Duration (days)
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Signs/Symptoms developed while in hospital:
General:___________________________________________
:__________________________________
Fever
Myalgia
Nausea
Back Pain
Vomiting
Cough
Diarrhea
Shortness of breath
Weight loss
Sinus problems
Anorexia
Abnormal Reflexes
Headache
Disorientation
Stiff neck
Lethargy/fatigue
Other general symptom/sign, specify:_
__________

Visual
Blurred vision
Diplopia
Photophobia
Other visual changes, specify:_

_______

Altered mental status
Dysphagia
Altered sense of taste
Aphasia
Facial numbness/Parathesia
Altered sense of smell
Ataxia
Hallucinations
Decerebrate posturing
Behavioral changes
Hemiparesis/Hemiplegia
Decorticate posturing
Coma
Hyperreflexia
Fixed, nonreactive pupils
Combativeness
Loss of balance
Dilated pupils
Confusion
Numbness
Nystagmus
Cranial nerve VI deficit
Seizures
Cranial nerve VII deficit
Upgoing toes
Cranial nerve XII deficit
Weakness
Other neurologic deficit, specify: _____
________
Other Cranial nerve deficit, specify:
Neurologic:_______________________________________________________________________________________
___
Skin Lesions:

Yes

No

Lesion type

If yes, please specify in table below:
Anatomic location

Ulcers
Plaques
Erythematous nodules
Other
Other Symptoms/Signs:
Other, specify:_

______________________

Size

Number
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Diagnostic Tests: Note please provide dates when possible. If date not available, provide hospital day (i.e. CSF tap on Hosp. Day 2)

LABORATORY TESTING
Date________________

CSF

Date_______________

Results

Date_______________

Results

Results

Opening pressure (mmH2O)
WBC count (per mm3 )
RBC count (per mm3 )
Neutrophil %
Monocyte %
Lymphocyte %
Bands %
Eosinophil %
Protein (mg/100ml)
Glucose (mg/100ml)
Cytokines
CSF Culture: *
CSF PCR: *
CSF latex agglutination: *
CSF mount:
Centrifuged
Stained
Centrifuged
Stained
Wet
Wet
Please indicate preparation
N
N
Amebae present? Y
Amebae present? Y
type and findings, if any
* Please provide results for all bacteria, viral and/or parasitic testing.
Presenting Lab Values:
RBC count (per mm3 )
Hematocrit %
WBC count (per mm3 )
Neutrophil %
Lymphocyte %
Monocyte %
Eosinophil %
Bands %
CD4 count (per mm3)
Protein (mg/100ml)

Date:
Results

Skin
Brain
Abscess
Other, specify:

Sodium (mEq/L)
Potassium (mEq/L)
Chloride (mEq/L)
Bicarbonate (mEq/L)
BUN (mg/100ml)
Creatinine (mg/100ml)
Glucose (mg/100ml)
Serology:
Date

Cultures for Free Living Amebae:
Source
Date
Blood

PCR for Free Living Amebae:
Source
Date
Blood
Skin
Result
Brain
Abscess
Other, specify:

Centrifuged
Stained
Wet
N
Amebae present? Y

Result
Negative
+ Naegleria
Negative
+ Naegleria
Negative
+ Naegleria
Negative
+ Naegleria
Negative
+ Naegleria

+ Balamuthia
+ Acanthamoeba
+ Balamuthia
+ Acanthamoeba
+ Balamuthia
+ Acanthamoeba
+ Balamuthia
+ Acanthamoeba
+ Balamuthia
+ Acanthamoeba

Result
Negative
+ Naegleria
Negative
+ Naegleria
Negative
+ Naegleria
Negative
+ Naegleria
Negative
+ Naegleria

+ Balamuthia
+ Acanthamoeba
+ Balamuthia
+ Acanthamoeba
+ Balamuthia
+ Acanthamoeba
+ Balamuthia
+ Acanthamoeba
+ Balamuthia
+ Acanthamoeba
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HISTOPATHOLOGY
Yes

Brain biopsy:

No

Unknown

Date:

Date:

Location
Timing

Antemortem

Results
(check all that
apply)

Postmortem

Unknown

Antemortem

Amebic trophozoites
Amebic cysts
Ameba, not specified
Hemorrhage
Necrosis
Encephalomalacia
Edema
Abscess
Vasculitis
Perivascular Inflammation
Thrombosis
Neovascularization
Neutrophillic inflammation / infiltrate
Lymphocytic inflammation / infiltrate
Granulomatous inflammation
Granuloma
Meningitis
Encephalitis
Meningoencephalitis

Postmortem

Unknown

Amebic trophozoites
Amebic cysts
Ameba, not specified
Hemorrhage
Necrosis
Encephalomalacia
Edema
Abscess
Vasculitis
Perivascular Inflammation
Thrombosis
Neovascularization
Neutrophillic inflammation / infiltrate
Lymphocytic inflammation / infiltrate
Granulomatous inflammation
Granuloma
Meningitis
Encephalitis
Meningoencephalitis

Other Results/
Comments

Yes

Skin biopsy:

No

Unknown

Date:
Location
Timing

Date:

Antemortem

Results

Postmortem

Unknown

Antemortem

No amebae seen
Amebic trophozoites
Amebic cysts
Amebae, not specified

Postmortem

Unknown

No amebae seen
Amebic trophozoites
Amebic cysts
Amebae, not specified

Other Results/
Comments
Yes

Sinus biopsy:

No

Unknown

Date:
Location
Timing
Results

Other Results/
Comments
Other biopsy results:

Date:

Antemortem

Postmortem

No amebae seen
Amebic trophozoites
Amebic cysts
Amebae, not specified

Unknown

Antemortem

Postmortem

No amebae seen
Amebic trophozoites
Amebic cysts
Amebae, not specified

Unknown
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DIAGNOSTIC IMAGING
CT: Date of First CT:
Lesion location: (please check all that apply)
Basal Ganglia
Left Occipital
Brainstem
Right Occipital
Right Cerebellum
Left Parietal
Left Cerebellum
Right Parietal
Left Frontal
Pons
Right Frontal
Spinal Cord
Lesion:

Left Temporal
Right Temporal
Thalamus
Other, specify:_

______________

(please check all that apply)

Abscess
Edema
Erosion
Hemorrhage
Herniation

Hyperdense
Hypodense
Infarcts
Mass
Multifocal lesions

Enhancing
Ring enhancing
Sinusitis
Ventriculomegaly
Other, specify: __

_______________

Addition
al
Descript
ion, if
needed:

Please list dates of subsequent CT scans and changes noted:
Date
Findings

MRI: Date of First MRI:
Lesion location: (please check all that apply)
Basal Ganglia
Left Occipital
Brainstem
Right Occipital
Right Cerebellum
Left Parietal
Left Cerebellum
Right Parietal
Left Frontal
Pons
Right Frontal
Spinal Cord
Lesion:
Abscess
Edema
Erosion
Hemorrhage
Herniation

Left Temporal
Right Temporal
Thalamus
Other, specify:_

______________

(please check all that apply)
Hyperdense
Hypodense
Infarcts
Mass
Multifocal lesions

Enhancing
Ring enhancing
Sinusitis
Ventriculomegaly
Other, specify: __

Please list dates of subsequent MRI scans and changes noted:
Date
Findings

_______________

Addition
al
Descript
ion, if
needed:
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Diagnosis:
Date of Diagnosis:

Admitting diagnosis:
Encephalitis
Meningitis

Meningoencephalitis
Other, Specify _
____________

Final diagnosis:
Date of Diagnosis:
GAE (Acanthamoeba spp.)
GAE (Balamuthia mandillaris)
Disseminated Acanthamoebiasis
Disseminated Balamuthiasis
Acanthamoeba rhinosinusitis
Balamuthia rhinosinusitis
Cutaneous acanthamoebiasis
Cutaneous balamuthiasis
Diagnosis Method:
Indirect Immunofluorescence (IIF)
PCR
Histopathology
CSF Wet Mount
Culture
Other, Specify:

Antemortem
Antemortem
Antemortem
Antemortem
Antemortem
Antemortem

PAM (Naegleria fowleri)
Other, specify:

Postmortem
Postmortem
Postmortem
Postmortem
Postmortem
Postmortem

Unknown
Unknown
Unknown
Unknown
Unknown
Unknown

Treatment:
Surgical resection:
Medications:

Yes

No

(please check all that apply)

Acyclovir
Albendazole
Amikacin
Amphotericin B
Amphotericin B lipid
Amphotericin B liposomal
Azithromycin
Ceftriaxone
Ciprofloxacin
Chloramphenicol
Clarithromycin
Co-trimoxazole
Dexamethasone

Ethambutol
Fluconazole
Flucytosine
Isoniazid
Itraconazole
Ketoconazole
Mannitol
Metronidazole
Miconazole
Miltefosine
Ornidazole
Pentamidine
Pyrimethamine

Rifampin
Steroid, specify__ ___
Streptomycin
Sulfonamide, specify______
Sulfadiazine
Topical Chlorhexidine
Trimethoprim/sulfa
Voriconazole
Other, specify____
____
Other, specify____
____
Other, specify____
____
Other, specify____
____
Other, specify____
____

If you checked any of the medications listed above, please list below with the start and stop dates, doses,
frequencies, and routes of administration. If an individual drug was given using multiple doses, over multiple
dates, and/or given by multiple routes, please indicate this in the rows below.
Medication

Start date:

Stop date:

Dose and Frequency

Route of Administration
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Other therapies:

(please check all that apply)
Start date:

Stop date:

IV fluids
Total Parenteral Nutrition (TPN)
Dialysis for renal failure
Other, specify_____________
Other, specify_____________
Other, specify_____________

Outcome:
Survived?

Yes

No

Unknown

If survived: Residual neurologic deficits?

If Yes, Please describe neurologic deficits: __
Date of discharge:

OR

No

Yes

Unknown

____________________________________________________

Date of death:

If died: Cause of death:
Brain death
Cardiorespiratory failure
Herniation
If died: Organs
If yes, which ones:

Removed life support
Other, specify:_
___________________
Yes

No

transplanted?

_________________________________

Please provide a brief description of the patient’s clinical course, complications, and any additional comments:

CDC USE ONLY:
1st DASH #
2nd DASH #
3rd DASH #
4th DASH #
5th DASH #
List additional
DASH #s:
Case report citation 1
Case report citation 2
List additional case citations

Calculated durations:
Incubation period (days):
Illness Onset to Admission (days):
Illness Onset to Death (days):
Exposure to Death (days):
Clinical Stage at presentation: ______

Epidemic Curve by Year of Report for Acanthamoeba spp. Cases

Appendix C: Epidemic Curves for Acanthamoeba and Balamuthia Cases
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Epidemic Curve by Year of Report for Balamuthia mandrillaris Cases
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Epidemic Curve by Age for Acanthamoeba spp. Cases
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Epidemic Curve by Age for Balamuthia mandrillaris Cases
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Appendix D: Treatment Regimens for Survivors
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Survivors of disseminated
acanthamoebiasis

Survivors of cutaneous
acanthamoebiasis

90

Survivors of Acanthamoeba rhinosinusitis
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Survivor of
disseminated
balamuthiasis

Survivors of Balamuthia GAE

